Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	0.0128 mg (N=1)	0.04 mg (N=2)	0.12 mg (N=4)	0.38 mg (N=2)	0.76 mg (N=7)	Total (N=68)
筋骨格系および結合組織障害 (continued)	0	0	1 (25.0%)	0	0	2 (2.9%)
背部痛	0	0	1 (25.0%)	0	0	2 (2.9%)
筋痙縮	0	0	0	0	1 (14.3%)	2 (2.9%)
筋肉痛	0	0	1 (25.0%)	0	0	2 (2.9%)
筋力低下	0	0	0	0	0	1 (1.5%)
頚部痛	0	0	0	0	0	1 (1.5%)
呼吸器、胸郭および縦隔障害	0	0	1 (25.0%)	0	1 (14.3%)	8 (11.8%)
呼吸困難	0	0	1 (25.0%)	0	1 (14.3%)	5 (7.4%)
発声障害	0	0	0	0	0	2 (2.9%)
頻呼吸	0	0	0	0	0	1 (1.5%)
皮膚および皮下組織障害	0	0	1 (25.0%)	0	1 (14.3%)	8 (11.8%)
発疹	0	0	0	0	1 (14.3%)	4 (5.9%)
紅斑	0	0	0	0	0	1 (1.5%)
そう痒症	0	0	0	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	1.5 mg (N=5)	3 mg (N=6)	6 mg (N=9)	12 mg (N=7)	24 mg (N=10)	Total (N=68)
筋骨格系および結合組織障害 (continued)	0	0	0	0	0	2 (2.9%)
背部痛	0	0	0	0	0	2 (2.9%)
筋痙縮	0	0	0	0	1 (10.0%)	2 (2.9%)
筋肉痛	0	0	0	0	0	2 (2.9%)
筋力低下	0	0	0	0	1 (10.0%)	1 (1.5%)
頚部痛	0	0	1 (11.1%)	0	0	1 (1.5%)
呼吸器、胸郭および縦隔障害	1 (20.0%)	0	2 (22.2%)	1 (14.3%)	1 (10.0%)	8 (11.8%)
呼吸困難	0	0	0	1 (14.3%)	1 (10.0%)	5 (7.4%)
発声障害	1 (20.0%)	0	1 (11.1%)	0	0	2 (2.9%)
頻呼吸	0	0	1 (11.1%)	0	0	1 (1.5%)
皮膚および皮下組織障害	0	1 (16.7%)	1 (11.1%)	2 (28.6%)	2 (20.0%)	8 (11.8%)
発疹	0	1 (16.7%)	0	1 (14.3%)	1 (10.0%)	4 (5.9%)
紅斑	0	0	0	1 (14.3%)	0	1 (1.5%)
そう痒症	0	0	0	0	1 (10.0%)	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose 48 mg (N=12)	 60 mg (N=3)	 Total (N=68)
筋骨格系および結合組織障害 (continued)	0	1 (33.3%)	2 (2.9%)
背部痛	0	1 (33.3%)	2 (2.9%)
筋痙縮	0	0	2 (2.9%)
筋肉痛	0	1 (33.3%)	2 (2.9%)
筋力低下	0	0	1 (1.5%)
頚部痛	0	0	1 (1.5%)
呼吸器、胸郭および縦隔障害	1 (8.3%)	0	8 (11.8%)
呼吸困難	1 (8.3%)	0	5 (7.4%)
発声障害	0	0	2 (2.9%)
頻呼吸	0	0	1 (1.5%)
皮膚および皮下組織障害	0	0	8 (11.8%)
発疹	0	0	4 (5.9%)
紅斑	0	0	1 (1.5%)
そう痒症	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	<=6 mg (N=36)	12 mg (N=7)	24 mg (N=10)	48 mg (N=12)	60 mg (N=3)	Total (N=68)
筋骨格系および結合組織障害 (continued)	1 (2.8%)	0	0	0	1 (33.3%)	2 (2.9%)
背部痛	1 (2.8%)	0	0	0	1 (33.3%)	2 (2.9%)
筋痙縮	1 (2.8%)	0	1 (10.0%)	0	0	2 (2.9%)
筋肉痛	1 (2.8%)	0	0	0	1 (33.3%)	2 (2.9%)
筋力低下	0	0	1 (10.0%)	0	0	1 (1.5%)
頚部痛	1 (2.8%)	0	0	0	0	1 (1.5%)
呼吸器、胸郭および縦隔障害	5 (13.9%)	1 (14.3%)	1 (10.0%)	1 (8.3%)	0	8 (11.8%)
呼吸困難	2 (5.6%)	1 (14.3%)	1 (10.0%)	1 (8.3%)	0	5 (7.4%)
発声障害	2 (5.6%)	0	0	0	0	2 (2.9%)
頻呼吸	1 (2.8%)	0	0	0	0	1 (1.5%)
皮膚および皮下組織障害	4 (11.1%)	2 (28.6%)	2 (20.0%)	0	0	8 (11.8%)
発疹	2 (5.6%)	1 (14.3%)	1 (10.0%)	0	0	4 (5.9%)
紅斑	0	1 (14.3%)	0	0	0	1 (1.5%)
そう痒症	0	0	1 (10.0%)	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	0.0128 mg (N=1)	0.04 mg (N=2)	0.12 mg (N=4)	0.38 mg (N=2)	0.76 mg (N=7)	Total (N=68)
皮膚および皮下組織障害 (continued)	0	0	0	0	0	1 (1.5%)
そう痒性皮疹	0	0	0	0	0	1 (1.5%)
皮膚剥脱	0	0	1 (25.0%)	0	0	1 (1.5%)
血管障害	0	0	0	0	0	7 (10.3%)
低血圧	0	0	0	0	0	4 (5.9%)
ほてり	0	0	0	0	0	2 (2.9%)
潮紅	0	0	0	0	0	1 (1.5%)
心臓障害	0	0	1 (25.0%)	0	0	4 (5.9%)
頻脈	0	0	0	0	0	2 (2.9%)
狭心症	0	0	1 (25.0%)	0	0	1 (1.5%)
心不全	0	0	0	0	0	1 (1.5%)
眼障害	0	0	0	0	0	4 (5.9%)
流涙増加	0	0	0	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	1.5 mg (N=5)	3 mg (N=6)	6 mg (N=9)	12 mg (N=7)	24 mg (N=10)	Total (N=68)
皮膚および皮下組織障害 (continued)	0	0	1 (11.1%)	0	0	1 (1.5%)
そう痒性皮疹	0	0	1 (11.1%)	0	0	1 (1.5%)
皮膚剥脱	0	0	0	0	0	1 (1.5%)
血管障害	0	1 (16.7%)	2 (22.2%)	1 (14.3%)	2 (20.0%)	7 (10.3%)
低血圧	0	0	2 (22.2%)	1 (14.3%)	1 (10.0%)	4 (5.9%)
ほてり	0	1 (16.7%)	0	0	0	2 (2.9%)
潮紅	0	0	0	0	1 (10.0%)	1 (1.5%)
心臓障害	1 (20.0%)	1 (16.7%)	1 (11.1%)	0	0	4 (5.9%)
頻脈	1 (20.0%)	0	1 (11.1%)	0	0	2 (2.9%)
狭心症	0	0	0	0	0	1 (1.5%)
心不全	0	1 (16.7%)	0	0	0	1 (1.5%)
眼障害	0	1 (16.7%)	0	1 (14.3%)	1 (10.0%)	4 (5.9%)
流涙増加	0	0	0	0	1 (10.0%)	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose 48 mg (N=12)	 60 mg (N=3)	 Total (N=68)
皮膚および皮下組織障害 (continued)	0	0	1 (1.5%)
そう痒性皮疹	0	0	1 (1.5%)
皮膚剥脱	0	0	1 (1.5%)
血管障害	1 (8.3%)	0	7 (10.3%)
低血圧	0	0	4 (5.9%)
ほてり	1 (8.3%)	0	2 (2.9%)
潮紅	0	0	1 (1.5%)
心臓障害	0	0	4 (5.9%)
頻脈	0	0	2 (2.9%)
狭心症	0	0	1 (1.5%)
心不全	0	0	1 (1.5%)
眼障害	0	1 (33.3%)	4 (5.9%)
流涙増加	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	<=6 mg (N=36)	12 mg (N=7)	24 mg (N=10)	48 mg (N=12)	60 mg (N=3)	Total (N=68)
皮膚および皮下組織障害 (continued)	1 (2.8%)	0	0	0	0	1 (1.5%)
そう痒性皮疹	1 (2.8%)	0	0	0	0	1 (1.5%)
皮膚剥脱	1 (2.8%)	0	0	0	0	1 (1.5%)
血管障害	3 (8.3%)	1 (14.3%)	2 (20.0%)	1 (8.3%)	0	7 (10.3%)
低血圧	2 (5.6%)	1 (14.3%)	1 (10.0%)	0	0	4 (5.9%)
ほてり	1 (2.8%)	0	0	1 (8.3%)	0	2 (2.9%)
潮紅	0	0	1 (10.0%)	0	0	1 (1.5%)
心臓障害	4 (11.1%)	0	0	0	0	4 (5.9%)
頻脈	2 (5.6%)	0	0	0	0	2 (2.9%)
狭心症	1 (2.8%)	0	0	0	0	1 (1.5%)
心不全	1 (2.8%)	0	0	0	0	1 (1.5%)
眼障害	1 (2.8%)	1 (14.3%)	1 (10.0%)	0	1 (33.3%)	4 (5.9%)
流涙増加	0	0	1 (10.0%)	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	0.0128 mg (N=1)	0.04 mg (N=2)	0.12 mg (N=4)	0.38 mg (N=2)	0.76 mg (N=7)	Total (N=68)
眼障害 (continued)	0	0	0	0	0	1 (1.5%)
眼窩周囲浮腫	0	0	0	0	0	1 (1.5%)
眼窩周囲腫脹	0	0	0	0	0	1 (1.5%)
眼瞼腫脹	0	0	0	0	0	1 (1.5%)
霧視	0	0	0	0	0	1 (1.5%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (14.3%)	3 (4.4%)
腫瘍フレア	0	0	0	0	0	2 (2.9%)
腫瘍疼痛	0	0	0	0	1 (14.3%)	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	1.5 mg (N=5)	3 mg (N=6)	6 mg (N=9)	12 mg (N=7)	24 mg (N=10)	Total (N=68)
眼障害 (continued)	0	0	0	0	0	1 (1.5%)
眼窩周囲浮腫	0	0	0	0	0	1 (1.5%)
眼窩周囲腫脹	0	1 (16.7%)	0	0	0	1 (1.5%)
眼瞼腫脹	0	1 (16.7%)	0	0	0	1 (1.5%)
霧視	0	0	0	1 (14.3%)	0	1 (1.5%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	0	0	1 (10.0%)	3 (4.4%)
腫瘍フレア	0	0	0	0	1 (10.0%)	2 (2.9%)
腫瘍疼痛	0	0	0	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose 48 mg (N=12)	 60 mg (N=3)	 Total (N=68)
眼障害 (continued)	0	1 (33.3%)	1 (1.5%)
眼窩周囲浮腫	0	1 (33.3%)	1 (1.5%)
眼窩周囲腫脹	0	0	1 (1.5%)
眼瞼腫脹	0	0	1 (1.5%)
霧視	0	0	1 (1.5%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (8.3%)	0	3 (4.4%)
腫瘍フレア	1 (8.3%)	0	2 (2.9%)
腫瘍疼痛	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 2 GEN3013 Related Treatment Emergent Adverse Events by SOC and PT

Dose Escalation Part - GEN3013 - Safety Set

System Organ Class Preferred Term	Full Dose					
	<=6 mg (N=36)	12 mg (N=7)	24 mg (N=10)	48 mg (N=12)	60 mg (N=3)	Total (N=68)
眼障害 (continued)	0	0	0	0	1 (33.3%)	1 (1.5%)
眼窩周囲浮腫	0	0	0	0	1 (33.3%)	1 (1.5%)
眼窩周囲腫脹	1 (2.8%)	0	0	0	0	1 (1.5%)
眼瞼腫脹	1 (2.8%)	0	0	0	0	1 (1.5%)
霧視	0	1 (14.3%)	0	0	0	1 (1.5%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (2.8%)	0	1 (10.0%)	1 (8.3%)	0	3 (4.4%)
腫瘍フレア	0	0	1 (10.0%)	1 (8.3%)	0	2 (2.9%)
腫瘍疼痛	1 (2.8%)	0	0	0	0	1 (1.5%)

Percentages are calculated based on number of subjects in safety set.
Drug relationship, action taken and severity are not collected for Adverse Events of Special Interest.
Cytokine Release Syndrome and on-treatment Clinical Tumor Lysis Syndrome were considered to be related to treatment.
Note: Multiple adverse events with same TEAE are only counted the one with maximum toxicity grade, if available, for each patient.
MedDRA version 24.1

Table 3

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
Subjects with at least one TEAE	138 (99.3%)	115 (82.7%)	18 (100%)	15 (83.3%)	156 (99.4%)	130 (82.8%)
一般・全身障害および投与部位の状態	91 (65.5%)	63 (45.3%)	10 (55.6%)	8 (44.4%)	101 (64.3%)	71 (45.2%)
発熱	32 (23.0%)	15 (10.8%)	5 (27.8%)	4 (22.2%)	37 (23.6%)	19 (12.1%)
疲労	33 (23.7%)	19 (13.7%)	3 (16.7%)	2 (11.1%)	36 (22.9%)	21 (13.4%)
注射部位反応	29 (20.9%)	29 (20.9%)	2 (11.1%)	2 (11.1%)	31 (19.7%)	31 (19.7%)
末梢性浮腫	16 (11.5%)	3 (2.2%)	1 (5.6%)	0	17 (10.8%)	3 (1.9%)
無力症	12 (8.6%)	5 (3.6%)	0	0	12 (7.6%)	5 (3.2%)
注射部位紅斑	12 (8.6%)	12 (8.6%)	0	0	12 (7.6%)	12 (7.6%)
悪寒	5 (3.6%)	3 (2.2%)	3 (16.7%)	1 (5.6%)	8 (5.1%)	4 (2.5%)
疼痛	8 (5.8%)	2 (1.4%)	0	0	8 (5.1%)	2 (1.3%)
注射部位疼痛	4 (2.9%)	4 (2.9%)	0	0	4 (2.5%)	4 (2.5%)
注射部位そう痒感	4 (2.9%)	4 (2.9%)	0	0	4 (2.5%)	4 (2.5%)
全身健康状態悪化	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0
倦怠感	3 (2.2%)	1 (0.7%)	0	0	3 (1.9%)	1 (0.6%)
浮腫	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
胸痛	2 (1.4%)	1 (0.7%)	0	0	2 (1.3%)	1 (0.6%)
顔面浮腫	2 (1.4%)	0	0	0	2 (1.3%)	0
注射部位肥厚	2 (1.4%)	2 (1.4%)	0	0	2 (1.3%)	2 (1.3%)
注射部位炎症	2 (1.4%)	2 (1.4%)	0	0	2 (1.3%)	2 (1.3%)
注射部位発疹	2 (1.4%)	2 (1.4%)	0	0	2 (1.3%)	2 (1.3%)
非心臓性胸痛	2 (1.4%)	0	0	0	2 (1.3%)	0
カテーテル留置部位分泌物	0	0	1 (5.6%)	0	1 (0.6%)	0
カテーテル留置部位紅斑	0	0	1 (5.6%)	0	1 (0.6%)	0
カテーテル留置部位発疹	1 (0.7%)	0	0	0	1 (0.6%)	0
胸部不快感	1 (0.7%)	0	0	0	1 (0.6%)	0
運動耐性低下	1 (0.7%)	0	0	0	1 (0.6%)	0
熱感	1 (0.7%)	0	0	0	1 (0.6%)	0
全身性浮腫	1 (0.7%)	0	0	0	1 (0.6%)	0
炎症	1 (0.7%)	0	0	0	1 (0.6%)	0
インフルエンザ様疾患	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
注射部位内出血	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
注射部位腫瘤	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
注射部位腫脹	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
注射部位蕁麻疹	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
限局性浮腫	1 (0.7%)	0	0	0	1 (0.6%)	0
粘膜の炎症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
末梢腫脹	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
体調不良	0	0	1 (5.6%)	0	1 (0.6%)	0
温度変化不耐症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
ワクチン接種部位反応	1 (0.7%)	0	0	0	1 (0.6%)	0
胃腸障害	89 (64.0%)	24 (17.3%)	9 (50.0%)	2 (11.1%)	98 (62.4%)	26 (16.6%)
下痢	29 (20.9%)	8 (5.8%)	3 (16.7%)	0	32 (20.4%)	8 (5.1%)
悪心	29 (20.9%)	10 (7.2%)	2 (11.1%)	1 (5.6%)	31 (19.7%)	11 (7.0%)
腹痛	21 (15.1%)	4 (2.9%)	1 (5.6%)	1 (5.6%)	22 (14.0%)	5 (3.2%)
便秘	18 (12.9%)	2 (1.4%)	2 (11.1%)	0	20 (12.7%)	2 (1.3%)
嘔吐	18 (12.9%)	2 (1.4%)	1 (5.6%)	0	19 (12.1%)	2 (1.3%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
上腹部痛	10 (7.2%)	1 (0.7%)	0	0	10 (6.4%)	1 (0.6%)
腹部不快感	7 (5.0%)	0	0	0	7 (4.5%)	0
消化不良	5 (3.6%)	0	1 (5.6%)	0	6 (3.8%)	0
口内乾燥	5 (3.6%)	1 (0.7%)	0	0	5 (3.2%)	1 (0.6%)
口内炎	5 (3.6%)	0	0	0	5 (3.2%)	0
嚥下障害	4 (2.9%)	0	0	0	4 (2.5%)	0
下腹部痛	2 (1.4%)	0	0	0	2 (1.3%)	0
胃食道逆流性疾患	1 (0.7%)	0	1 (5.6%)	1 (5.6%)	2 (1.3%)	1 (0.6%)
嚥下痛	2 (1.4%)	0	0	0	2 (1.3%)	0
口腔内痛	0	0	2 (11.1%)	0	2 (1.3%)	0
腹部圧痛	1 (0.7%)	0	0	0	1 (0.6%)	0
腹壁腫瘤	1 (0.7%)	0	0	0	1 (0.6%)	0
空気嚥下	1 (0.7%)	0	0	0	1 (0.6%)	0
肛門水疱	1 (0.7%)	0	0	0	1 (0.6%)	0
アフタ性潰瘍	1 (0.7%)	0	0	0	1 (0.6%)	0
便意切迫	0	0	1 (5.6%)	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
齲歯	1 (0.7%)	0	0	0	1 (0.6%)	0
十二指腸穿孔	1 (0.7%)	0	0	0	1 (0.6%)	0
十二指腸潰瘍	1 (0.7%)	0	0	0	1 (0.6%)	0
変色便	0	0	1 (5.6%)	0	1 (0.6%)	0
鼓腸	1 (0.7%)	0	0	0	1 (0.6%)	0
食中毒	0	0	1 (5.6%)	0	1 (0.6%)	0
胃炎	1 (0.7%)	0	0	0	1 (0.6%)	0
胃腸障害	1 (0.7%)	0	0	0	1 (0.6%)	0
血便排泄	1 (0.7%)	0	0	0	1 (0.6%)	0
腸管穿孔	1 (0.7%)	0	0	0	1 (0.6%)	0
腹腔内血腫	1 (0.7%)	0	0	0	1 (0.6%)	0
大腸ポリープ	1 (0.7%)	0	0	0	1 (0.6%)	0
口腔内潰瘍形成	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
口腔知覚不全	1 (0.7%)	0	0	0	1 (0.6%)	0
膵炎	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
小腸出血	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
歯痛	1 (0.7%)	0	0	0	1 (0.6%)	0
免疫系障害	70 (50.4%)	68 (48.9%)	10 (55.6%)	10 (55.6%)	80 (51.0%)	78 (49.7%)
サイトカイン放出症候群	68 (48.9%)	68 (48.9%)	10 (55.6%)	10 (55.6%)	78 (49.7%)	78 (49.7%)
低γグロブリン血症	4 (2.9%)	2 (1.4%)	0	0	4 (2.5%)	2 (1.3%)
食物アレルギー	1 (0.7%)	0	0	0	1 (0.6%)	0
体液性免疫不全	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
ヨウ素アレルギー	1 (0.7%)	0	0	0	1 (0.6%)	0
サルコイドーシス	1 (0.7%)	0	0	0	1 (0.6%)	0
感染症および寄生虫症	61 (43.9%)	11 (7.9%)	10 (55.6%)	1 (5.6%)	71 (45.2%)	12 (7.6%)
肺炎	8 (5.8%)	1 (0.7%)	0	0	8 (5.1%)	1 (0.6%)
尿路感染	7 (5.0%)	0	1 (5.6%)	0	8 (5.1%)	0
ＣＯＶＩＤ－１９	7 (5.0%)	0	0	0	7 (4.5%)	0
上気道感染	5 (3.6%)	2 (1.4%)	1 (5.6%)	0	6 (3.8%)	2 (1.3%)
口腔カンジダ症	5 (3.6%)	2 (1.4%)	0	0	5 (3.2%)	2 (1.3%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
蜂巣炎	2 (1.4%)	0	2 (11.1%)	0	4 (2.5%)	0
敗血症	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)
口腔ヘルペス	2 (1.4%)	2 (1.4%)	1 (5.6%)	0	3 (1.9%)	2 (1.3%)
菌血症	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
ＣＯＶＩＤ－１９肺炎	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
大腸菌性尿路感染	2 (1.4%)	1 (0.7%)	0	0	2 (1.3%)	1 (0.6%)
単純ヘルペス	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
膿疱性皮疹	1 (0.7%)	1 (0.7%)	1 (5.6%)	0	2 (1.3%)	1 (0.6%)
気道感染	2 (1.4%)	0	0	0	2 (1.3%)	0
敗血症性ショック	2 (1.4%)	0	0	0	2 (1.3%)	0
皮膚感染	2 (1.4%)	0	0	0	2 (1.3%)	0
無症候性ＣＯＶＩＤ－１９	1 (0.7%)	0	0	0	1 (0.6%)	0
細菌性腎盂腎炎	1 (0.7%)	0	0	0	1 (0.6%)	0
体部白癬	1 (0.7%)	0	0	0	1 (0.6%)	0
気管支炎	0	0	1 (5.6%)	0	1 (0.6%)	0
カンピロバクター胃腸炎	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
カンピロバクター感染	1 (0.7%)	0	0	0	1 (0.6%)	0
カンジダ感染	1 (0.7%)	0	0	0	1 (0.6%)	0
サイトメガロウイルス感染	1 (0.7%)	0	0	0	1 (0.6%)	0
サイトメガロウイルス感染再燃	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
医療機器関連感染	1 (0.7%)	0	0	0	1 (0.6%)	0
腸球菌感染	1 (0.7%)	0	0	0	1 (0.6%)	0
感染性小腸結腸炎	1 (0.7%)	0	0	0	1 (0.6%)	0
毛包炎	1 (0.7%)	0	0	0	1 (0.6%)	0
胃腸炎	1 (0.7%)	0	0	0	1 (0.6%)	0
ウイルス性胃腸炎	1 (0.7%)	0	0	0	1 (0.6%)	0
ヘリコバクター感染	1 (0.7%)	0	0	0	1 (0.6%)	0
帯状疱疹	1 (0.7%)	0	0	0	1 (0.6%)	0
喉頭炎	1 (0.7%)	0	0	0	1 (0.6%)	0
下気道感染	1 (0.7%)	0	0	0	1 (0.6%)	0
粘膜感染	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
鼓膜炎	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
食道カンジダ症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
膵炎	1 (0.7%)	0	0	0	1 (0.6%)	0
骨髄炎	1 (0.7%)	0	0	0	1 (0.6%)	0
咽頭炎	1 (0.7%)	0	0	0	1 (0.6%)	0
進行性多巣性白質脳症	1 (0.7%)	0	0	0	1 (0.6%)	0
腎盂腎炎	1 (0.7%)	0	0	0	1 (0.6%)	0
ＲＳウイルス感染	1 (0.7%)	0	0	0	1 (0.6%)	0
鼻炎	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
ライノウイルス感染	1 (0.7%)	0	0	0	1 (0.6%)	0
唾液腺炎	1 (0.7%)	0	0	0	1 (0.6%)	0
ブドウ球菌性菌血症	0	0	1 (5.6%)	0	1 (0.6%)	0
ブドウ球菌感染	1 (0.7%)	0	0	0	1 (0.6%)	0
腸球菌性尿路感染	1 (0.7%)	0	0	0	1 (0.6%)	0
真菌性尿路感染	1 (0.7%)	0	0	0	1 (0.6%)	0
シュードモナス性尿路感染	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
尿路性敗血症	1 (0.7%)	0	0	0	1 (0.6%)	0
血液およびリンパ系障害	58 (41.7%)	38 (27.3%)	7 (38.9%)	5 (27.8%)	65 (41.4%)	43 (27.4%)
好中球減少症	32 (23.0%)	26 (18.7%)	2 (11.1%)	2 (11.1%)	34 (21.7%)	28 (17.8%)
貧血	26 (18.7%)	9 (6.5%)	2 (11.1%)	0	28 (17.8%)	9 (5.7%)
血小板減少症	20 (14.4%)	7 (5.0%)	1 (5.6%)	0	21 (13.4%)	7 (4.5%)
リンパ球減少症	6 (4.3%)	3 (2.2%)	1 (5.6%)	1 (5.6%)	7 (4.5%)	4 (2.5%)
白血球減少症	5 (3.6%)	3 (2.2%)	0	0	5 (3.2%)	3 (1.9%)
発熱性好中球減少症	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)
鉄欠乏性貧血	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
リンパ節痛	1 (0.7%)	0	0	0	1 (0.6%)	0
リンパ節症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
リンパ球増加症	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
好中球増加症	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
筋骨格系および結合組織障害	52 (37.4%)	11 (7.9%)	6 (33.3%)	3 (16.7%)	58 (36.9%)	14 (8.9%)
背部痛	13 (9.4%)	0	3 (16.7%)	1 (5.6%)	16 (10.2%)	1 (0.6%)
関節痛	11 (7.9%)	3 (2.2%)	0	0	11 (7.0%)	3 (1.9%)
筋痙縮	6 (4.3%)	1 (0.7%)	1 (5.6%)	1 (5.6%)	7 (4.5%)	2 (1.3%)
筋肉痛	6 (4.3%)	3 (2.2%)	0	0	6 (3.8%)	3 (1.9%)
筋骨格痛	5 (3.6%)	0	0	0	5 (3.2%)	0
四肢痛	3 (2.2%)	2 (1.4%)	2 (11.1%)	1 (5.6%)	5 (3.2%)	3 (1.9%)
筋骨格系胸痛	3 (2.2%)	1 (0.7%)	1 (5.6%)	0	4 (2.5%)	1 (0.6%)
骨痛	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0
筋力低下	3 (2.2%)	0	0	0	3 (1.9%)	0
筋骨格硬直	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0
側腹部痛	1 (0.7%)	0	1 (5.6%)	1 (5.6%)	2 (1.3%)	1 (0.6%)
頚部痛	2 (1.4%)	0	0	0	2 (1.3%)	0
変形性関節症	2 (1.4%)	0	0	0	2 (1.3%)	0
骨粗鬆症	2 (1.4%)	0	0	0	2 (1.3%)	0
脊椎痛	2 (1.4%)	0	0	0	2 (1.3%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
腋窩腫瘤	1 (0.7%)	0	0	0	1 (0.6%)	0
瘻孔	1 (0.7%)	0	0	0	1 (0.6%)	0
肛径部痛	1 (0.7%)	0	0	0	1 (0.6%)	0
四肢不快感	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
ミオパチー	1 (0.7%)	0	0	0	1 (0.6%)	0
頚部腫瘤	1 (0.7%)	0	0	0	1 (0.6%)	0
顎痛	1 (0.7%)	0	0	0	1 (0.6%)	0
代謝および栄養障害	50 (36.0%)	9 (6.5%)	5 (27.8%)	1 (5.6%)	55 (35.0%)	10 (6.4%)
食欲減退	18 (12.9%)	3 (2.2%)	1 (5.6%)	0	19 (12.1%)	3 (1.9%)
低カリウム血症	12 (8.6%)	1 (0.7%)	0	0	12 (7.6%)	1 (0.6%)
低マグネシウム血症	9 (6.5%)	2 (1.4%)	1 (5.6%)	1 (5.6%)	10 (6.4%)	3 (1.9%)
低リン血症	8 (5.8%)	2 (1.4%)	0	0	8 (5.1%)	2 (1.3%)
低ナトリウム血症	6 (4.3%)	1 (0.7%)	0	0	6 (3.8%)	1 (0.6%)
高血糖	4 (2.9%)	0	0	0	4 (2.5%)	0
高カリウム血症	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
低アルブミン血症	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)
高カルシウム血症	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0
脱水	2 (1.4%)	0	0	0	2 (1.3%)	0
鉄欠乏	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
ステロイド糖尿病	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
腫瘍崩壊症候群	2 (1.4%)	2 (1.4%)	0	0	2 (1.3%)	2 (1.3%)
糖尿病	0	0	1 (5.6%)	0	1 (0.6%)	0
高尿酸血症	1 (0.7%)	0	0	0	1 (0.6%)	0
血液量増加症	1 (0.7%)	0	0	0	1 (0.6%)	0
低カルシウム血症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
低血糖	1 (0.7%)	0	0	0	1 (0.6%)	0
低蛋白血症	1 (0.7%)	0	0	0	1 (0.6%)	0
代謝性アシドーシス	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
２型糖尿病	1 (0.7%)	0	0	0	1 (0.6%)	0
ビタミンD欠乏	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
ビタミンK欠乏	1 (0.7%)	0	0	0	1 (0.6%)	0
神経系障害	46 (33.1%)	19 (13.7%)	8 (44.4%)	4 (22.2%)	54 (34.4%)	23 (14.6%)
頭痛	17 (12.2%)	6 (4.3%)	4 (22.2%)	3 (16.7%)	21 (13.4%)	9 (5.7%)
免疫エフェクター細胞関連神経毒性症候群	9 (6.5%)	9 (6.5%)	1 (5.6%)	1 (5.6%)	10 (6.4%)	10 (6.4%)
浮動性めまい	6 (4.3%)	0	1 (5.6%)	0	7 (4.5%)	0
錯感覚	6 (4.3%)	1 (0.7%)	0	0	6 (3.8%)	1 (0.6%)
振戦	6 (4.3%)	2 (1.4%)	0	0	6 (3.8%)	2 (1.3%)
末梢性ニューロパチー	3 (2.2%)	0	1 (5.6%)	0	4 (2.5%)	0
感覚鈍麻	3 (2.2%)	0	0	0	3 (1.9%)	0
嗜眠	3 (2.2%)	2 (1.4%)	0	0	3 (1.9%)	2 (1.3%)
末梢性感覚ニューロパチー	3 (2.2%)	0	0	0	3 (1.9%)	0
記憶障害	2 (1.4%)	1 (0.7%)	0	0	2 (1.3%)	1 (0.6%)
失神	1 (0.7%)	1 (0.7%)	1 (5.6%)	0	2 (1.3%)	1 (0.6%)
急性多発ニューロパチー	1 (0.7%)	0	0	0	1 (0.6%)	0
運動失調	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
中枢神経系病変	1 (0.7%)	0	0	0	1 (0.6%)	0
脳虚血	1 (0.7%)	0	0	0	1 (0.6%)	0
ステロイド反応性脳橋血管周囲強化を伴う慢性リンパ球性炎症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
認知障害	1 (0.7%)	0	0	0	1 (0.6%)	0
味覚不全	1 (0.7%)	0	0	0	1 (0.6%)	0
顔面麻痺	1 (0.7%)	0	0	0	1 (0.6%)	0
水頭症	1 (0.7%)	0	0	0	1 (0.6%)	0
味覚減退	1 (0.7%)	0	0	0	1 (0.6%)	0
意識消失	1 (0.7%)	0	0	0	1 (0.6%)	0
神経系障害	1 (0.7%)	0	0	0	1 (0.6%)	0
神経痛	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
多発ニューロパチー	0	0	1 (5.6%)	0	1 (0.6%)	0
下肢静止不能症候群	1 (0.7%)	0	0	0	1 (0.6%)	0
坐骨神経痛	1 (0.7%)	0	0	0	1 (0.6%)	0
会話障害	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
脊髄圧迫	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
一過性脳虚血発作	1 (0.7%)	0	0	0	1 (0.6%)	0
臨床検査	45 (32.4%)	18 (12.9%)	4 (22.2%)	2 (11.1%)	49 (31.2%)	20 (12.7%)
好中球数減少	7 (5.0%)	4 (2.9%)	3 (16.7%)	2 (11.1%)	10 (6.4%)	6 (3.8%)
アラニンアミノトランスフェラーゼ増加	7 (5.0%)	4 (2.9%)	2 (11.1%)	1 (5.6%)	9 (5.7%)	5 (3.2%)
アスパラギン酸アミノトランスフェラーゼ増加	4 (2.9%)	3 (2.2%)	2 (11.1%)	1 (5.6%)	6 (3.8%)	4 (2.5%)
C－反応性蛋白増加	6 (4.3%)	2 (1.4%)	0	0	6 (3.8%)	2 (1.3%)
体重減少	6 (4.3%)	0	0	0	6 (3.8%)	0
血中アルカリホスファターゼ増加	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)
血中クレアチニン増加	4 (2.9%)	0	0	0	4 (2.5%)	0
血中乳酸脱水素酵素増加	4 (2.9%)	0	0	0	4 (2.5%)	0
γ－グルタミルトランスフェラーゼ増加	3 (2.2%)	0	0	0	3 (1.9%)	0
リンパ球数減少	3 (2.2%)	1 (0.7%)	0	0	3 (1.9%)	1 (0.6%)
血小板数減少	3 (2.2%)	2 (1.4%)	0	0	3 (1.9%)	2 (1.3%)
血中免疫グロブリンG減少	2 (1.4%)	1 (0.7%)	0	0	2 (1.3%)	1 (0.6%)
フィブリンDダイマー増加	2 (1.4%)	2 (1.4%)	0	0	2 (1.3%)	2 (1.3%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
白血球数減少	2 (1.4%)	0	0	0	2 (1.3%)	0
活性化部分トロンボプラスチン時間延長	1 (0.7%)	0	0	0	1 (0.6%)	0
血中ビリルビン増加	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
血中ブドウ糖増加	1 (0.7%)	0	0	0	1 (0.6%)	0
血中ナトリウム減少	1 (0.7%)	0	0	0	1 (0.6%)	0
血中尿素増加	1 (0.7%)	0	0	0	1 (0.6%)	0
血中尿酸増加	1 (0.7%)	0	0	0	1 (0.6%)	0
体温上昇	1 (0.7%)	0	0	0	1 (0.6%)	0
カルシウムイオン減少	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
ブドウ糖負荷試験異常	1 (0.7%)	0	0	0	1 (0.6%)	0
眼圧上昇	1 (0.7%)	0	0	0	1 (0.6%)	0
リパーゼ増加	1 (0.7%)	0	0	0	1 (0.6%)	0
肝機能検査値上昇	1 (0.7%)	0	0	0	1 (0.6%)	0
酸素飽和度低下	1 (0.7%)	0	0	0	1 (0.6%)	0
総蛋白増加	1 (0.7%)	0	0	0	1 (0.6%)	0
血清フェリチン減少	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
トランスアミナーゼ上昇	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
トロポニン増加	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
白血球数増加	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
皮膚および皮下組織障害	37 (26.6%)	18 (12.9%)	6 (33.3%)	3 (16.7%)	43 (27.4%)	21 (13.4%)
そう痒症	9 (6.5%)	4 (2.9%)	2 (11.1%)	1 (5.6%)	11 (7.0%)	5 (3.2%)
発疹	7 (5.0%)	6 (4.3%)	2 (11.1%)	1 (5.6%)	9 (5.7%)	7 (4.5%)
紅斑	5 (3.6%)	3 (2.2%)	0	0	5 (3.2%)	3 (1.9%)
皮膚病変	4 (2.9%)	0	0	0	4 (2.5%)	0
脱毛症	2 (1.4%)	1 (0.7%)	1 (5.6%)	0	3 (1.9%)	1 (0.6%)
水疱性皮膚炎	3 (2.2%)	1 (0.7%)	0	0	3 (1.9%)	1 (0.6%)
皮膚乾燥	3 (2.2%)	1 (0.7%)	0	0	3 (1.9%)	1 (0.6%)
多汗症	3 (2.2%)	2 (1.4%)	0	0	3 (1.9%)	2 (1.3%)
水疱	1 (0.7%)	1 (0.7%)	1 (5.6%)	0	2 (1.3%)	1 (0.6%)
脂漏性皮膚炎	2 (1.4%)	0	0	0	2 (1.3%)	0
敏感肌	2 (1.4%)	1 (0.7%)	0	0	2 (1.3%)	1 (0.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
蕁麻疹	1 (0.7%)	0	1 (5.6%)	1 (5.6%)	2 (1.3%)	1 (0.6%)
ざ瘡	0	0	1 (5.6%)	0	1 (0.6%)	0
水疱破裂	1 (0.7%)	0	0	0	1 (0.6%)	0
ざ瘡様皮膚炎	0	0	1 (5.6%)	0	1 (0.6%)	0
皮脂欠乏性湿疹	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
寝汗	1 (0.7%)	0	0	0	1 (0.6%)	0
手掌紅斑	1 (0.7%)	0	0	0	1 (0.6%)	0
丘疹	1 (0.7%)	0	0	0	1 (0.6%)	0
紫斑	1 (0.7%)	0	0	0	1 (0.6%)	0
紅斑性皮疹	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
斑状丘疹状皮疹	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
皮膚剥脱	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
皮膚硬結	1 (0.7%)	0	0	0	1 (0.6%)	0
皮膚線条	1 (0.7%)	0	0	0	1 (0.6%)	0
皮膚潰瘍	0	0	1 (5.6%)	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
呼吸器、胸郭および縦隔障害	38 (27.3%)	7 (5.0%)	4 (22.2%)	0	42 (26.8%)	7 (4.5%)
胸水	11 (7.9%)	2 (1.4%)	3 (16.7%)	0	14 (8.9%)	2 (1.3%)
咳嗽	11 (7.9%)	1 (0.7%)	0	0	11 (7.0%)	1 (0.6%)
呼吸困難	11 (7.9%)	1 (0.7%)	0	0	11 (7.0%)	1 (0.6%)
低酸素症	3 (2.2%)	0	0	0	3 (1.9%)	0
湿性咳嗽	2 (1.4%)	1 (0.7%)	1 (5.6%)	0	3 (1.9%)	1 (0.6%)
肺塞栓症	3 (2.2%)	0	0	0	3 (1.9%)	0
鼻閉	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
気管支痙攣	1 (0.7%)	0	0	0	1 (0.6%)	0
発声障害	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
労作性呼吸困難	1 (0.7%)	0	0	0	1 (0.6%)	0
喀血	1 (0.7%)	0	0	0	1 (0.6%)	0
肺浸潤	1 (0.7%)	0	0	0	1 (0.6%)	0
口腔咽頭痛	1 (0.7%)	0	0	0	1 (0.6%)	0
副鼻腔不快感	1 (0.7%)	0	0	0	1 (0.6%)	0
胸膜瘻	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
胸膜炎	1 (0.7%)	0	0	0	1 (0.6%)	0
肺臓炎	1 (0.7%)	0	0	0	1 (0.6%)	0
呼吸不全	1 (0.7%)	0	0	0	1 (0.6%)	0
副鼻腔うっ血	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
咽喉刺激感	1 (0.7%)	0	0	0	1 (0.6%)	0
傷害、中毒および処置合併症	21 (15.1%)	1 (0.7%)	4 (22.2%)	1 (5.6%)	25 (15.9%)	2 (1.3%)
挫傷	6 (4.3%)	0	1 (5.6%)	1 (5.6%)	7 (4.5%)	1 (0.6%)
転倒	4 (2.9%)	0	2 (11.1%)	0	6 (3.8%)	0
注入に伴う反応	2 (1.4%)	0	0	0	2 (1.3%)	0
皮膚擦過傷	2 (1.4%)	0	0	0	2 (1.3%)	0
節足動物咬傷	1 (0.7%)	0	0	0	1 (0.6%)	0
節足動物刺傷	1 (0.7%)	0	0	0	1 (0.6%)	0
大腿骨頚部骨折	1 (0.7%)	0	0	0	1 (0.6%)	0
切開部位発疹	1 (0.7%)	0	0	0	1 (0.6%)	0
靭帯捻挫	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
肉離れ	1 (0.7%)	0	0	0	1 (0.6%)	0
処置後出血	0	0	1 (5.6%)	0	1 (0.6%)	0
処置後そう痒感	1 (0.7%)	0	0	0	1 (0.6%)	0
処置による疼痛	1 (0.7%)	0	0	0	1 (0.6%)	0
リコール現象	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
皮膚裂傷	1 (0.7%)	0	0	0	1 (0.6%)	0
脊椎圧迫骨折	1 (0.7%)	0	0	0	1 (0.6%)	0
脊髄ショック	1 (0.7%)	0	0	0	1 (0.6%)	0
硬膜下血腫	1 (0.7%)	0	0	0	1 (0.6%)	0
歯牙破折	0	0	1 (5.6%)	0	1 (0.6%)	0
手首関節骨折	1 (0.7%)	0	0	0	1 (0.6%)	0
精神障害	23 (16.5%)	3 (2.2%)	2 (11.1%)	0	25 (15.9%)	3 (1.9%)
不眠症	13 (9.4%)	2 (1.4%)	2 (11.1%)	0	15 (9.6%)	2 (1.3%)
不安	4 (2.9%)	0	0	0	4 (2.5%)	0
精神状態変化	3 (2.2%)	1 (0.7%)	0	0	3 (1.9%)	1 (0.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
うつ病	2 (1.4%)	0	0	0	2 (1.3%)	0
激越	1 (0.7%)	0	0	0	1 (0.6%)	0
錯乱状態	1 (0.7%)	0	0	0	1 (0.6%)	0
譫妄	1 (0.7%)	0	0	0	1 (0.6%)	0
感情的苦悩	1 (0.7%)	0	0	0	1 (0.6%)	0
神経過敏	1 (0.7%)	0	0	0	1 (0.6%)	0
血管障害	21 (15.1%)	7 (5.0%)	4 (22.2%)	1 (5.6%)	25 (15.9%)	8 (5.1%)
低血圧	9 (6.5%)	5 (3.6%)	2 (11.1%)	0	11 (7.0%)	5 (3.2%)
高血圧	4 (2.9%)	1 (0.7%)	0	0	4 (2.5%)	1 (0.6%)
血腫	3 (2.2%)	0	0	0	3 (1.9%)	0
ほてり	1 (0.7%)	0	1 (5.6%)	1 (5.6%)	2 (1.3%)	1 (0.6%)
表在性静脈血栓症	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
血栓性静脈炎	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
深部静脈血栓症	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
頚静脈血栓症	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
リンパ浮腫	0	0	1 (5.6%)	0	1 (0.6%)	0
起立性低血圧	0	0	1 (5.6%)	0	1 (0.6%)	0
血栓症	1 (0.7%)	0	0	0	1 (0.6%)	0
静脈閉塞	1 (0.7%)	0	0	0	1 (0.6%)	0
静脈血栓症	1 (0.7%)	0	0	0	1 (0.6%)	0
心臓障害	20 (14.4%)	3 (2.2%)	4 (22.2%)	2 (11.1%)	24 (15.3%)	5 (3.2%)
頻脈	6 (4.3%)	1 (0.7%)	2 (11.1%)	1 (5.6%)	8 (5.1%)	2 (1.3%)
洞性頻脈	4 (2.9%)	1 (0.7%)	1 (5.6%)	1 (5.6%)	5 (3.2%)	2 (1.3%)
心房細動	2 (1.4%)	0	1 (5.6%)	0	3 (1.9%)	0
心不全	3 (2.2%)	0	0	0	3 (1.9%)	0
上室性頻脈	2 (1.4%)	0	0	0	2 (1.3%)	0
狭心症	1 (0.7%)	0	0	0	1 (0.6%)	0
徐脈	1 (0.7%)	0	0	0	1 (0.6%)	0
心タンポナーデ	0	0	1 (5.6%)	0	1 (0.6%)	0
ＱＴ延長症候群	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
心筋梗塞	1 (0.7%)	0	0	0	1 (0.6%)	0
心嚢液貯留	1 (0.7%)	0	0	0	1 (0.6%)	0
心膜炎	1 (0.7%)	0	0	0	1 (0.6%)	0
洞性徐脈	1 (0.7%)	1 (0.7%)	0	0	1 (0.6%)	1 (0.6%)
上室性期外収縮	1 (0.7%)	0	0	0	1 (0.6%)	0
腎および尿路障害	17 (12.2%)	0	4 (22.2%)	0	21 (13.4%)	0
急性腎障害	4 (2.9%)	0	3 (16.7%)	0	7 (4.5%)	0
排尿困難	4 (2.9%)	0	1 (5.6%)	0	5 (3.2%)	0
夜間頻尿	3 (2.2%)	0	0	0	3 (1.9%)	0
尿閉	2 (1.4%)	0	0	0	2 (1.3%)	0
膀胱刺激症状	1 (0.7%)	0	0	0	1 (0.6%)	0
糖尿	1 (0.7%)	0	0	0	1 (0.6%)	0
血尿	1 (0.7%)	0	0	0	1 (0.6%)	0
尿意切迫	0	0	1 (5.6%)	0	1 (0.6%)	0
頻尿	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
腎不全	1 (0.7%)	0	0	0	1 (0.6%)	0
腎機能障害	1 (0.7%)	0	0	0	1 (0.6%)	0
排尿躊躇	1 (0.7%)	0	0	0	1 (0.6%)	0
尿失禁	1 (0.7%)	0	0	0	1 (0.6%)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	14 (10.1%)	5 (3.6%)	2 (11.1%)	1 (5.6%)	16 (10.2%)	6 (3.8%)
腫瘍フレア	4 (2.9%)	4 (2.9%)	0	0	4 (2.5%)	4 (2.5%)
基底細胞癌	3 (2.2%)	0	0	0	3 (1.9%)	0
腫瘍疼痛	2 (1.4%)	2 (1.4%)	1 (5.6%)	1 (5.6%)	3 (1.9%)	3 (1.9%)
骨髄異形成症候群	2 (1.4%)	0	0	0	2 (1.3%)	0
良性新生物	1 (0.7%)	0	0	0	1 (0.6%)	0
癌疼痛	1 (0.7%)	0	0	0	1 (0.6%)	0
感染性新生物	1 (0.7%)	0	0	0	1 (0.6%)	0
脂肪腫	1 (0.7%)	0	0	0	1 (0.6%)	0
肺新生物	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
腫瘍熱	0	0	1 (5.6%)	0	1 (0.6%)	0
眼障害	10 (7.2%)	0	1 (5.6%)	0	11 (7.0%)	0
ドライアイ	2 (1.4%)	0	0	0	2 (1.3%)	0
硝子体浮遊物	2 (1.4%)	0	0	0	2 (1.3%)	0
失明	1 (0.7%)	0	0	0	1 (0.6%)	0
白内障	1 (0.7%)	0	0	0	1 (0.6%)	0
結膜出血	1 (0.7%)	0	0	0	1 (0.6%)	0
複視	1 (0.7%)	0	0	0	1 (0.6%)	0
眼出血	1 (0.7%)	0	0	0	1 (0.6%)	0
眼部腫脹	1 (0.7%)	0	0	0	1 (0.6%)	0
眼充血	0	0	1 (5.6%)	0	1 (0.6%)	0
霧視	1 (0.7%)	0	0	0	1 (0.6%)	0
視力障害	1 (0.7%)	0	0	0	1 (0.6%)	0
硝子体剥離	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
生殖系および乳房障害	4 (2.9%)	0	2 (11.1%)	0	6 (3.8%)	0
乳房痛	1 (0.7%)	0	1 (5.6%)	0	2 (1.3%)	0
良性前立腺肥大症	1 (0.7%)	0	0	0	1 (0.6%)	0
乳頭痛	1 (0.7%)	0	0	0	1 (0.6%)	0
陰茎紅斑	1 (0.7%)	0	0	0	1 (0.6%)	0
陰嚢浮腫	0	0	1 (5.6%)	0	1 (0.6%)	0
内分泌障害	3 (2.2%)	0	2 (11.1%)	1 (5.6%)	5 (3.2%)	1 (0.6%)
グルココルチコイド欠乏症	0	0	1 (5.6%)	0	1 (0.6%)	0
甲状腺機能亢進症	1 (0.7%)	0	0	0	1 (0.6%)	0
下垂体機能低下症	1 (0.7%)	0	0	0	1 (0.6%)	0
甲状腺機能低下症	0	0	1 (5.6%)	1 (5.6%)	1 (0.6%)	1 (0.6%)
甲状腺炎	1 (0.7%)	0	0	0	1 (0.6%)	0
肝胆道系障害	5 (3.6%)	0	0	0	5 (3.2%)	0
胆管炎	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	aNHL Cohort					
	DLBCL (N=139)		Other (N=18)		LBCL (N=157)	
	All	Related	All	Related	All	Related
胆嚢炎	1 (0.7%)	0	0	0	1 (0.6%)	0
胆汁うっ滞	1 (0.7%)	0	0	0	1 (0.6%)	0
肝毒性	1 (0.7%)	0	0	0	1 (0.6%)	0
肝損傷	1 (0.7%)	0	0	0	1 (0.6%)	0
耳および迷路障害	2 (1.4%)	0	0	0	2 (1.3%)	0
中耳滲出液	1 (0.7%)	0	0	0	1 (0.6%)	0
回転性めまい	1 (0.7%)	0	0	0	1 (0.6%)	0
製品の問題	0	0	1 (5.6%)	0	1 (0.6%)	0
医療機器閉塞	0	0	1 (5.6%)	0	1 (0.6%)	0
外科および内科処置	1 (0.7%)	0	0	0	1 (0.6%)	0
抜歯	1 (0.7%)	0	0	0	1 (0.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Table 4

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
Subjects with at least one TEAE	89 (96.7%)	84 (91.3%)	13 (100%)	13 (100%)	102 (97.1%)	97 (92.4%)
一般・全身障害および投与部位の状態	67 (72.8%)	56 (60.9%)	11 (84.6%)	9 (69.2%)	78 (74.3%)	65 (61.9%)
注射部位反応	31 (33.7%)	30 (32.6%)	7 (53.8%)	7 (53.8%)	38 (36.2%)	37 (35.2%)
疲労	30 (32.6%)	18 (19.6%)	4 (30.8%)	3 (23.1%)	34 (32.4%)	21 (20.0%)
発熱	24 (26.1%)	13 (14.1%)	3 (23.1%)	2 (15.4%)	27 (25.7%)	15 (14.3%)
注射部位紅斑	11 (12.0%)	10 (10.9%)	0	0	11 (10.5%)	10 (9.5%)
末梢性浮腫	9 (9.8%)	0	2 (15.4%)	0	11 (10.5%)	0
無力症	7 (7.6%)	3 (3.3%)	1 (7.7%)	1 (7.7%)	8 (7.6%)	4 (3.8%)
注射部位発疹	7 (7.6%)	7 (7.6%)	1 (7.7%)	1 (7.7%)	8 (7.6%)	8 (7.6%)
悪寒	5 (5.4%)	4 (4.3%)	0	0	5 (4.8%)	4 (3.8%)
倦怠感	3 (3.3%)	2 (2.2%)	1 (7.7%)	1 (7.7%)	4 (3.8%)	3 (2.9%)
非心臓性胸痛	4 (4.3%)	1 (1.1%)	0	0	4 (3.8%)	1 (1.0%)
注射部位浮腫	3 (3.3%)	3 (3.3%)	0	0	3 (2.9%)	3 (2.9%)
注射部位そう痒感	3 (3.3%)	3 (3.3%)	0	0	3 (2.9%)	3 (2.9%)
疼痛	3 (3.3%)	2 (2.2%)	0	0	3 (2.9%)	2 (1.9%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
インフルエンザ様疾患	1 (1.1%)	1 (1.1%)	1 (7.7%)	1 (7.7%)	2 (1.9%)	2 (1.9%)
注射部位炎症	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
末梢腫脹	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
カテーテル留置部位炎症	1 (1.1%)	0	0	0	1 (1.0%)	0
カテーテル留置部位疼痛	1 (1.1%)	0	0	0	1 (1.0%)	0
胸部不快感	1 (1.1%)	0	0	0	1 (1.0%)	0
胸痛	1 (1.1%)	0	0	0	1 (1.0%)	0
熱感	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
低体温	1 (1.1%)	0	0	0	1 (1.0%)	0
注射部位疼痛	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
腫瘤	1 (1.1%)	0	0	0	1 (1.0%)	0
医療機器不快感	1 (1.1%)	0	0	0	1 (1.0%)	0
医療機器による疼痛	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
粘膜の炎症	1 (1.1%)	0	0	0	1 (1.0%)	0
体調不良	0	0	1 (7.7%)	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
顔面腫脹	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
免疫系障害	59 (64.1%)	59 (64.1%)	12 (92.3%)	12 (92.3%)	71 (67.6%)	71 (67.6%)
サイトカイン放出症候群	58 (63.0%)	58 (63.0%)	12 (92.3%)	12 (92.3%)	70 (66.7%)	70 (66.7%)
低γグロブリン血症	3 (3.3%)	1 (1.1%)	0	0	3 (2.9%)	1 (1.0%)
薬物過敏症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
成人多臓器炎症症候群	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
血清病	0	0	1 (7.7%)	1 (7.7%)	1 (1.0%)	1 (1.0%)
感染症および寄生虫症	50 (54.3%)	12 (13.0%)	9 (69.2%)	2 (15.4%)	59 (56.2%)	14 (13.3%)
尿路感染	9 (9.8%)	0	2 (15.4%)	0	11 (10.5%)	0
ＣＯＶＩＤ－１９	9 (9.8%)	1 (1.1%)	1 (7.7%)	0	10 (9.5%)	1 (1.0%)
肺炎	6 (6.5%)	2 (2.2%)	1 (7.7%)	0	7 (6.7%)	2 (1.9%)
上気道感染	6 (6.5%)	1 (1.1%)	1 (7.7%)	0	7 (6.7%)	1 (1.0%)
上咽頭炎	3 (3.3%)	2 (2.2%)	1 (7.7%)	0	4 (3.8%)	2 (1.9%)
ニューモシスチス・イロベチイ肺炎	3 (3.3%)	1 (1.1%)	1 (7.7%)	0	4 (3.8%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
ＣＯＶＩＤ－１９肺炎	3 (3.3%)	0	0	0	3 (2.9%)	0
膀胱炎	2 (2.2%)	0	1 (7.7%)	0	3 (2.9%)	0
帯状疱疹	3 (3.3%)	0	0	0	3 (2.9%)	0
下気道感染	2 (2.2%)	0	1 (7.7%)	0	3 (2.9%)	0
カンジダ感染	2 (2.2%)	0	0	0	2 (1.9%)	0
口腔カンジダ症	1 (1.1%)	0	1 (7.7%)	1 (7.7%)	2 (1.9%)	1 (1.0%)
口腔ヘルペス	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
咽頭炎	1 (1.1%)	0	1 (7.7%)	0	2 (1.9%)	0
気道感染	2 (2.2%)	0	0	0	2 (1.9%)	0
鼻炎	2 (2.2%)	0	0	0	2 (1.9%)	0
敗血症性ショック	2 (2.2%)	0	0	0	2 (1.9%)	0
ブドウ球菌感染	2 (2.2%)	0	0	0	2 (1.9%)	0
急性副鼻腔炎	1 (1.1%)	0	0	0	1 (1.0%)	0
アデノウイルス感染	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
細菌尿	1 (1.1%)	0	0	0	1 (1.0%)	0
気管支炎	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
気管支肺アスペルギルス症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
蜂巣炎	1 (1.1%)	0	0	0	1 (1.0%)	0
クラミジア感染	1 (1.1%)	0	0	0	1 (1.0%)	0
結膜炎	1 (1.1%)	0	0	0	1 (1.0%)	0
サイトメガロウイルス性脈絡網膜炎	1 (1.1%)	0	0	0	1 (1.0%)	0
サイトメガロウイルス感染	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
サイトメガロウイルス感染再燃	0	0	1 (7.7%)	1 (7.7%)	1 (1.0%)	1 (1.0%)
医療機器関連感染	1 (1.1%)	0	0	0	1 (1.0%)	0
真菌感染	1 (1.1%)	0	0	0	1 (1.0%)	0
せつ	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
ウイルス性胃腸炎	1 (1.1%)	0	0	0	1 (1.0%)	0
性器感染	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
真菌性性器感染	1 (1.1%)	0	0	0	1 (1.0%)	0
単純ヘルペス	0	0	1 (7.7%)	0	1 (1.0%)	0
単純ヘルペス再燃	1 (1.1%)	0	0	0	1 (1.0%)	0
ヘルペスウイルス感染	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
感染性胸水	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
感染による気管支拡張症の増悪	1 (1.1%)	0	0	0	1 (1.0%)	0
限局性感染	0	0	1 (7.7%)	0	1 (1.0%)	0
髄膜炎	1 (1.1%)	0	0	0	1 (1.0%)	0
壊死性筋膜炎	0	0	1 (7.7%)	0	1 (1.0%)	0
食道カンジダ症	1 (1.1%)	0	0	0	1 (1.0%)	0
爪囲炎	0	0	1 (7.7%)	0	1 (1.0%)	0
腎盂腎炎	1 (1.1%)	0	0	0	1 (1.0%)	0
ＲＳウイルス感染	1 (1.1%)	0	0	0	1 (1.0%)	0
副鼻腔炎	1 (1.1%)	0	0	0	1 (1.0%)	0
皮膚感染	1 (1.1%)	0	0	0	1 (1.0%)	0
ブドウ球菌性菌血症	1 (1.1%)	0	0	0	1 (1.0%)	0
真菌性舌感染	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
細菌性上気道感染	1 (1.1%)	0	0	0	1 (1.0%)	0
腸球菌性尿路感染	1 (1.1%)	0	0	0	1 (1.0%)	0
水痘帯状疱疹ウイルス感染	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
創傷感染	1 (1.1%)	0	0	0	1 (1.0%)	0
胃腸障害	51 (55.4%)	21 (22.8%)	5 (38.5%)	1 (7.7%)	56 (53.3%)	22 (21.0%)
下痢	23 (25.0%)	9 (9.8%)	1 (7.7%)	0	24 (22.9%)	9 (8.6%)
悪心	15 (16.3%)	5 (5.4%)	1 (7.7%)	0	16 (15.2%)	5 (4.8%)
便秘	11 (12.0%)	2 (2.2%)	1 (7.7%)	0	12 (11.4%)	2 (1.9%)
嘔吐	6 (6.5%)	2 (2.2%)	2 (15.4%)	0	8 (7.6%)	2 (1.9%)
腹痛	7 (7.6%)	2 (2.2%)	0	0	7 (6.7%)	2 (1.9%)
消化不良	7 (7.6%)	4 (4.3%)	0	0	7 (6.7%)	4 (3.8%)
上腹部痛	4 (4.3%)	1 (1.1%)	0	0	4 (3.8%)	1 (1.0%)
胃食道逆流性疾患	4 (4.3%)	0	0	0	4 (3.8%)	0
口内炎	3 (3.3%)	1 (1.1%)	1 (7.7%)	0	4 (3.8%)	1 (1.0%)
アフタ性潰瘍	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
口内乾燥	2 (2.2%)	0	0	0	2 (1.9%)	0
口腔内痛	2 (2.2%)	0	0	0	2 (1.9%)	0
腹部不快感	0	0	1 (7.7%)	1 (7.7%)	1 (1.0%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
腹部膨満	1 (1.1%)	0	0	0	1 (1.0%)	0
腹部ヘルニア	1 (1.1%)	0	0	0	1 (1.0%)	0
下腹部痛	1 (1.1%)	0	0	0	1 (1.0%)	0
肛門出血	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
口角口唇炎	1 (1.1%)	0	0	0	1 (1.0%)	0
腹水	0	0	1 (7.7%)	0	1 (1.0%)	0
腸憩室	1 (1.1%)	0	0	0	1 (1.0%)	0
小腸炎	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
軟便	1 (1.1%)	0	0	0	1 (1.0%)	0
鼓腸	1 (1.1%)	0	0	0	1 (1.0%)	0
胃腸出血	1 (1.1%)	0	0	0	1 (1.0%)	0
腹腔内血腫	1 (1.1%)	0	0	0	1 (1.0%)	0
過敏性腸症候群	1 (1.1%)	0	0	0	1 (1.0%)	0
大腸ポリープ	1 (1.1%)	0	0	0	1 (1.0%)	0
口唇出血	1 (1.1%)	0	0	0	1 (1.0%)	0
口腔内潰瘍形成	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
食道痛	1 (1.1%)	0	0	0	1 (1.0%)	0
耳下腺管閉塞	1 (1.1%)	0	0	0	1 (1.0%)	0
舌潰瘍	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
皮膚および皮下組織障害	42 (45.7%)	23 (25.0%)	3 (23.1%)	1 (7.7%)	45 (42.9%)	24 (22.9%)
発疹	7 (7.6%)	2 (2.2%)	2 (15.4%)	0	9 (8.6%)	2 (1.9%)
紅斑	8 (8.7%)	7 (7.6%)	0	0	8 (7.6%)	7 (6.7%)
そう痒症	5 (5.4%)	3 (3.3%)	0	0	5 (4.8%)	3 (2.9%)
手掌・足底発赤知覚不全症候群	4 (4.3%)	3 (3.3%)	0	0	4 (3.8%)	3 (2.9%)
斑状丘疹状皮疹	4 (4.3%)	2 (2.2%)	0	0	4 (3.8%)	2 (1.9%)
皮膚乾燥	3 (3.3%)	2 (2.2%)	0	0	3 (2.9%)	2 (1.9%)
多汗症	3 (3.3%)	2 (2.2%)	0	0	3 (2.9%)	2 (1.9%)
寝汗	3 (3.3%)	1 (1.1%)	0	0	3 (2.9%)	1 (1.0%)
皮膚病変	2 (2.2%)	0	1 (7.7%)	1 (7.7%)	3 (2.9%)	1 (1.0%)
皮膚剥脱	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
皮膚毒性	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
ざ瘡	1 (1.1%)	0	0	0	1 (1.0%)	0
光線角化症	1 (1.1%)	0	0	0	1 (1.0%)	0
水疱	1 (1.1%)	0	0	0	1 (1.0%)	0
皮膚嚢腫	1 (1.1%)	0	0	0	1 (1.0%)	0
全身性剥脱性皮膚炎	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
湿疹	1 (1.1%)	0	0	0	1 (1.0%)	0
過角化	1 (1.1%)	0	0	0	1 (1.0%)	0
間擦疹	1 (1.1%)	0	0	0	1 (1.0%)	0
汗疹	1 (1.1%)	0	0	0	1 (1.0%)	0
皮膚疼痛	1 (1.1%)	0	0	0	1 (1.0%)	0
乾癬	1 (1.1%)	0	0	0	1 (1.0%)	0
紅斑性皮疹	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
丘疹性皮疹	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
そう痒性皮疹	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
小水疱性皮疹	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
皮膚分泌物	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
皮膚硬結	1 (1.1%)	0	0	0	1 (1.0%)	0
皮膚腫瘤	1 (1.1%)	0	0	0	1 (1.0%)	0
皮膚潰瘍	0	0	1 (7.7%)	0	1 (1.0%)	0
神経系障害	43 (46.7%)	21 (22.8%)	1 (7.7%)	0	44 (41.9%)	21 (20.0%)
頭痛	19 (20.7%)	7 (7.6%)	0	0	19 (18.1%)	7 (6.7%)
浮動性めまい	10 (10.9%)	4 (4.3%)	0	0	10 (9.5%)	4 (3.8%)
免疫エフェクター細胞関連神経毒性症候群	8 (8.7%)	8 (8.7%)	0	0	8 (7.6%)	8 (7.6%)
嗜眠	3 (3.3%)	1 (1.1%)	0	0	3 (2.9%)	1 (1.0%)
錯感覚	3 (3.3%)	2 (2.2%)	0	0	3 (2.9%)	2 (1.9%)
末梢性ニューロパチー	2 (2.2%)	0	0	0	2 (1.9%)	0
振戦	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
失語症	1 (1.1%)	0	0	0	1 (1.0%)	0
ベル麻痺	1 (1.1%)	0	0	0	1 (1.0%)	0
頚髄神経根障害	1 (1.1%)	0	0	0	1 (1.0%)	0
過眠症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
感覚鈍麻	0	0	1 (7.7%)	0	1 (1.0%)	0
記憶障害	1 (1.1%)	0	0	0	1 (1.0%)	0
神経痛	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
多発ニューロパチー	1 (1.1%)	0	0	0	1 (1.0%)	0
ヘルペス後神経痛	1 (1.1%)	0	0	0	1 (1.0%)	0
坐骨神経痛	1 (1.1%)	0	0	0	1 (1.0%)	0
失神	1 (1.1%)	0	0	0	1 (1.0%)	0
一過性脳虚血発作	1 (1.1%)	0	0	0	1 (1.0%)	0
血液およびリンパ系障害	32 (34.8%)	26 (28.3%)	8 (61.5%)	5 (38.5%)	40 (38.1%)	31 (29.5%)
好中球減少症	16 (17.4%)	16 (17.4%)	6 (46.2%)	3 (23.1%)	22 (21.0%)	19 (18.1%)
貧血	11 (12.0%)	6 (6.5%)	2 (15.4%)	1 (7.7%)	13 (12.4%)	7 (6.7%)
血小板減少症	5 (5.4%)	3 (3.3%)	3 (23.1%)	2 (15.4%)	8 (7.6%)	5 (4.8%)
リンパ球減少症	6 (6.5%)	5 (5.4%)	1 (7.7%)	1 (7.7%)	7 (6.7%)	6 (5.7%)
白血球減少症	3 (3.3%)	3 (3.3%)	0	0	3 (2.9%)	3 (2.9%)
リンパ節痛	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
発熱性好中球減少症	1 (1.1%)	0	0	0	1 (1.0%)	0
リンパ節症	1 (1.1%)	0	0	0	1 (1.0%)	0
好中球増加症	0	0	1 (7.7%)	0	1 (1.0%)	0
臨床検査	32 (34.8%)	23 (25.0%)	8 (61.5%)	5 (38.5%)	40 (38.1%)	28 (26.7%)
アラニンアミノトランスフェラーゼ増加	6 (6.5%)	5 (5.4%)	2 (15.4%)	1 (7.7%)	8 (7.6%)	6 (5.7%)
血中クレアチニン増加	7 (7.6%)	2 (2.2%)	1 (7.7%)	1 (7.7%)	8 (7.6%)	3 (2.9%)
好中球数減少	6 (6.5%)	6 (6.5%)	2 (15.4%)	2 (15.4%)	8 (7.6%)	8 (7.6%)
血小板数減少	3 (3.3%)	2 (2.2%)	3 (23.1%)	3 (23.1%)	6 (5.7%)	5 (4.8%)
リンパ球数減少	4 (4.3%)	3 (3.3%)	1 (7.7%)	1 (7.7%)	5 (4.8%)	4 (3.8%)
アスパラギン酸アミノトランスフェラーゼ増加	2 (2.2%)	2 (2.2%)	2 (15.4%)	1 (7.7%)	4 (3.8%)	3 (2.9%)
血中アルカリホスファターゼ増加	2 (2.2%)	2 (2.2%)	2 (15.4%)	1 (7.7%)	4 (3.8%)	3 (2.9%)
血中乳酸脱水素酵素増加	1 (1.1%)	0	2 (15.4%)	0	3 (2.9%)	0
γ－グルタミルトランスフェラーゼ増加	2 (2.2%)	1 (1.1%)	1 (7.7%)	0	3 (2.9%)	1 (1.0%)
体重減少	2 (2.2%)	0	1 (7.7%)	0	3 (2.9%)	0
血中ビリルビン増加	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
Ｃ－反応性蛋白増加	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
心電図ＱＴ延長	1 (1.1%)	0	1 (7.7%)	0	2 (1.9%)	0
血清フェリチン増加	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
血中コレステロール増加	1 (1.1%)	0	0	0	1 (1.0%)	0
血中フィブリノゲン減少	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
血中カリウム減少	1 (1.1%)	0	0	0	1 (1.0%)	0
血中尿酸増加	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
ＣＤ４リンパ球減少	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
心雑音	1 (1.1%)	0	0	0	1 (1.0%)	0
フィブリンＤダイマー増加	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
トランスアミナーゼ上昇	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
白血球数減少	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
呼吸器、胸郭および縦隔障害	33 (35.9%)	6 (6.5%)	4 (30.8%)	0	37 (35.2%)	6 (5.7%)
呼吸困難	15 (16.3%)	2 (2.2%)	1 (7.7%)	0	16 (15.2%)	2 (1.9%)
咳嗽	13 (14.1%)	0	0	0	13 (12.4%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
口腔咽頭痛	4 (4.3%)	1 (1.1%)	0	0	4 (3.8%)	1 (1.0%)
労作性呼吸困難	3 (3.3%)	0	0	0	3 (2.9%)	0
胸水	2 (2.2%)	1 (1.1%)	1 (7.7%)	0	3 (2.9%)	1 (1.0%)
肺塞栓症	3 (3.3%)	0	0	0	3 (2.9%)	0
発声障害	2 (2.2%)	0	0	0	2 (1.9%)	0
しゃっくり	1 (1.1%)	1 (1.1%)	1 (7.7%)	0	2 (1.9%)	1 (1.0%)
鼻漏	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
気管支肺症	1 (1.1%)	0	0	0	1 (1.0%)	0
気管支痙攣	0	0	1 (7.7%)	0	1 (1.0%)	0
間質性肺疾患	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
肺陰影	1 (1.1%)	0	0	0	1 (1.0%)	0
湿性咳嗽	1 (1.1%)	0	0	0	1 (1.0%)	0
肺うっ血	0	0	1 (7.7%)	0	1 (1.0%)	0
ラ音	1 (1.1%)	0	0	0	1 (1.0%)	0
副鼻腔うっ血	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
代謝および栄養障害	31 (33.7%)	10 (10.9%)	4 (30.8%)	0	35 (33.3%)	10 (9.5%)
食欲減退	7 (7.6%)	4 (4.3%)	0	0	7 (6.7%)	4 (3.8%)
高血糖	5 (5.4%)	0	2 (15.4%)	0	7 (6.7%)	0
低マグネシウム血症	6 (6.5%)	2 (2.2%)	1 (7.7%)	0	7 (6.7%)	2 (1.9%)
低カリウム血症	3 (3.3%)	1 (1.1%)	2 (15.4%)	0	5 (4.8%)	1 (1.0%)
鉄欠乏	5 (5.4%)	0	0	0	5 (4.8%)	0
低ナトリウム血症	4 (4.3%)	2 (2.2%)	0	0	4 (3.8%)	2 (1.9%)
２型糖尿病	4 (4.3%)	1 (1.1%)	0	0	4 (3.8%)	1 (1.0%)
低カルシウム血症	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
脱水	1 (1.1%)	0	0	0	1 (1.0%)	0
高カルシウム血症	1 (1.1%)	0	0	0	1 (1.0%)	0
高フェリチン血症	1 (1.1%)	0	0	0	1 (1.0%)	0
高カリウム血症	1 (1.1%)	0	0	0	1 (1.0%)	0
高リン血症	0	0	1 (7.7%)	0	1 (1.0%)	0
低リン血症	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
栄養障害	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
筋骨格系および結合組織障害	29 (31.5%)	9 (9.8%)	6 (46.2%)	1 (7.7%)	35 (33.3%)	10 (9.5%)
関節痛	9 (9.8%)	2 (2.2%)	0	0	9 (8.6%)	2 (1.9%)
背部痛	7 (7.6%)	3 (3.3%)	1 (7.7%)	0	8 (7.6%)	3 (2.9%)
四肢痛	5 (5.4%)	1 (1.1%)	3 (23.1%)	0	8 (7.6%)	1 (1.0%)
筋痙縮	6 (6.5%)	2 (2.2%)	1 (7.7%)	0	7 (6.7%)	2 (1.9%)
骨痛	4 (4.3%)	2 (2.2%)	0	0	4 (3.8%)	2 (1.9%)
筋骨格系胸痛	3 (3.3%)	1 (1.1%)	1 (7.7%)	0	4 (3.8%)	1 (1.0%)
筋肉痛	2 (2.2%)	1 (1.1%)	1 (7.7%)	1 (7.7%)	3 (2.9%)	2 (1.9%)
関節炎	2 (2.2%)	0	0	0	2 (1.9%)	0
筋力低下	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
筋骨格痛	2 (2.2%)	0	0	0	2 (1.9%)	0
頚部痛	1 (1.1%)	0	1 (7.7%)	0	2 (1.9%)	0
末梢性ニューロパチー	1 (1.1%)	0	0	0	1 (1.0%)	0
骨粗鬆症性骨折	0	0	1 (7.7%)	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
顎痛	1 (1.1%)	0	0	0	1 (1.0%)	0
サルコペニア	0	0	1 (7.7%)	0	1 (1.0%)	0
腱障害	1 (1.1%)	0	0	0	1 (1.0%)	0
精神障害	17 (18.5%)	3 (3.3%)	1 (7.7%)	0	18 (17.1%)	3 (2.9%)
不眠症	10 (10.9%)	0	0	0	10 (9.5%)	0
激越	2 (2.2%)	0	1 (7.7%)	0	3 (2.9%)	0
錯乱状態	1 (1.1%)	1 (1.1%)	1 (7.7%)	0	2 (1.9%)	1 (1.0%)
うつ病	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
易刺激性	2 (2.2%)	0	0	0	2 (1.9%)	0
不安	1 (1.1%)	0	0	0	1 (1.0%)	0
習慣性咳嗽	1 (1.1%)	0	0	0	1 (1.0%)	0
幻覚	1 (1.1%)	0	0	0	1 (1.0%)	0
精神状態変化	1 (1.1%)	0	0	0	1 (1.0%)	0
落ち着きのなさ	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
チック	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
傷害、中毒および処置合併症	11 (12.0%)	1 (1.1%)	5 (38.5%)	0	16 (15.2%)	1 (1.0%)
転倒	3 (3.3%)	0	2 (15.4%)	0	5 (4.8%)	0
皮膚裂傷	3 (3.3%)	0	0	0	3 (2.9%)	0
節足動物咬傷	1 (1.1%)	0	0	0	1 (1.0%)	0
凍瘡	1 (1.1%)	0	0	0	1 (1.0%)	0
挫傷	0	0	1 (7.7%)	0	1 (1.0%)	0
前腕骨折	0	0	1 (7.7%)	0	1 (1.0%)	0
股関節部骨折	0	0	1 (7.7%)	0	1 (1.0%)	0
注入に伴う反応	1 (1.1%)	0	0	0	1 (1.0%)	0
四肢損傷	1 (1.1%)	0	0	0	1 (1.0%)	0
処置による疼痛	0	0	1 (7.7%)	0	1 (1.0%)	0
肋骨骨折	1 (1.1%)	0	0	0	1 (1.0%)	0
脊椎骨折	0	0	1 (7.7%)	0	1 (1.0%)	0
ワクチン接種合併症	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
血管確保部位炎症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
腎および尿路障害	12 (13.0%)	2 (2.2%)	2 (15.4%)	0	14 (13.3%)	2 (1.9%)
急性腎障害	5 (5.4%)	1 (1.1%)	0	0	5 (4.8%)	1 (1.0%)
頻尿	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
排尿躊躇	2 (2.2%)	0	0	0	2 (1.9%)	0
尿閉	1 (1.1%)	0	1 (7.7%)	0	2 (1.9%)	0
排尿困難	1 (1.1%)	0	0	0	1 (1.0%)	0
糖尿	0	0	1 (7.7%)	0	1 (1.0%)	0
夜間頻尿	1 (1.1%)	0	0	0	1 (1.0%)	0
腎機能障害	1 (1.1%)	0	0	0	1 (1.0%)	0
耳および迷路障害	7 (7.6%)	0	2 (15.4%)	0	9 (8.6%)	0
耳鳴	2 (2.2%)	0	0	0	2 (1.9%)	0
回転性めまい	2 (2.2%)	0	0	0	2 (1.9%)	0
難聴	0	0	1 (7.7%)	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
耳不快感	1 (1.1%)	0	0	0	1 (1.0%)	0
耳痛	1 (1.1%)	0	0	0	1 (1.0%)	0
耳部腫脹	1 (1.1%)	0	0	0	1 (1.0%)	0
耳管開放	0	0	1 (7.7%)	0	1 (1.0%)	0
中耳の炎症	0	0	1 (7.7%)	0	1 (1.0%)	0
血管障害	7 (7.6%)	1 (1.1%)	2 (15.4%)	0	9 (8.6%)	1 (1.0%)
低血圧	2 (2.2%)	0	1 (7.7%)	0	3 (2.9%)	0
ほてり	2 (2.2%)	0	0	0	2 (1.9%)	0
深部静脈血栓症	1 (1.1%)	0	0	0	1 (1.0%)	0
血腫	0	0	1 (7.7%)	0	1 (1.0%)	0
高血圧	1 (1.1%)	0	0	0	1 (1.0%)	0
起立性低血圧	1 (1.1%)	0	0	0	1 (1.0%)	0
血栓症	1 (1.1%)	0	0	0	1 (1.0%)	0
血管炎	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
眼障害	7 (7.6%)	1 (1.1%)	1 (7.7%)	0	8 (7.6%)	1 (1.0%)
霧視	3 (3.3%)	0	0	0	3 (2.9%)	0
ドライアイ	1 (1.1%)	0	0	0	1 (1.0%)	0
眼痛	1 (1.1%)	0	0	0	1 (1.0%)	0
眼の異常感覚	1 (1.1%)	0	0	0	1 (1.0%)	0
眼そう痒症	0	0	1 (7.7%)	0	1 (1.0%)	0
硝子体出血	1 (1.1%)	0	0	0	1 (1.0%)	0
眼球乾燥症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	7 (7.6%)	0	1 (7.7%)	0	8 (7.6%)	0
血管免疫芽球性Ｔ細胞性リンパ腫	1 (1.1%)	0	0	0	1 (1.0%)	0
外耳の悪性新生物	1 (1.1%)	0	0	0	1 (1.0%)	0
膵管内乳頭粘液性腫瘍	0	0	1 (7.7%)	0	1 (1.0%)	0
大腸の良性新生物	1 (1.1%)	0	0	0	1 (1.0%)	0
リンパ腫の転化	1 (1.1%)	0	0	0	1 (1.0%)	0
肺扁平上皮癌	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
腫瘍熱	1 (1.1%)	0	0	0	1 (1.0%)	0
腫瘍疼痛	1 (1.1%)	0	0	0	1 (1.0%)	0
心臓障害	6 (6.5%)	0	1 (7.7%)	0	7 (6.7%)	0
心房細動	2 (2.2%)	0	0	0	2 (1.9%)	0
動悸	2 (2.2%)	0	0	0	2 (1.9%)	0
頻脈	1 (1.1%)	0	1 (7.7%)	0	2 (1.9%)	0
洞性徐脈	1 (1.1%)	0	0	0	1 (1.0%)	0
生殖系および乳房障害	4 (4.3%)	0	1 (7.7%)	0	5 (4.8%)	0
骨盤痛	2 (2.2%)	0	0	0	2 (1.9%)	0
亀頭包皮炎	1 (1.1%)	0	0	0	1 (1.0%)	0
前立腺閉塞	1 (1.1%)	0	0	0	1 (1.0%)	0
前立腺炎	1 (1.1%)	0	0	0	1 (1.0%)	0
外陰膣の炎症	0	0	1 (7.7%)	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	iNHL Cohort					
	FL 1-3A (N=92)		Other (N=13)		Overall (N=105)	
	All	Related	All	Related	All	Related
肝胆道系障害	3 (3.3%)	2 (2.2%)	0	0	3 (2.9%)	2 (1.9%)
胆汁うっ滞	2 (2.2%)	2 (2.2%)	0	0	2 (1.9%)	2 (1.9%)
胆嚢炎	1 (1.1%)	0	0	0	1 (1.0%)	0
内分泌障害	2 (2.2%)	1 (1.1%)	0	0	2 (1.9%)	1 (1.0%)
甲状腺機能低下症	1 (1.1%)	1 (1.1%)	0	0	1 (1.0%)	1 (1.0%)
甲状腺腫瘤	1 (1.1%)	0	0	0	1 (1.0%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Table 5

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
Subjects with at least one TEAE	35 (94.6%)	30 (81.1%)
一般・全身障害および投与部位の状態	23 (62.2%)	12 (32.4%)
疲労	10 (27.0%)	4 (10.8%)
発熱	9 (24.3%)	2 (5.4%)
注射部位反応	3 (8.1%)	3 (8.1%)
無力症	2 (5.4%)	0
胸痛	2 (5.4%)	0
悪寒	2 (5.4%)	2 (5.4%)
全身健康状態悪化	2 (5.4%)	1 (2.7%)
全身性浮腫	2 (5.4%)	0
注射部位紅斑	2 (5.4%)	2 (5.4%)
薬剤離脱症候群	1 (2.7%)	0
顔面痛	1 (2.7%)	0
注射部位疼痛	1 (2.7%)	1 (2.7%)
粘膜の炎症	1 (2.7%)	0
多臓器機能不全症候群	1 (2.7%)	1 (2.7%)
末梢性浮腫	1 (2.7%)	0
疼痛	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
穿刺部位紅斑	1 (2.7%)	1 (2.7%)
免疫系障害	20 (54.1%)	20 (54.1%)
サイトカイン放出症候群	20 (54.1%)	20 (54.1%)
胃腸障害	16 (43.2%)	5 (13.5%)
便秘	6 (16.2%)	0
悪心	5 (13.5%)	3 (8.1%)
下痢	4 (10.8%)	0
腹痛	3 (8.1%)	0
消化不良	2 (5.4%)	1 (2.7%)
腹部腫瘤	1 (2.7%)	0
下腹部痛	1 (2.7%)	0
上腹部痛	1 (2.7%)	0
血性下痢	1 (2.7%)	0
口内乾燥	1 (2.7%)	1 (2.7%)
胃食道逆流性疾患	1 (2.7%)	1 (2.7%)
血便排泄	1 (2.7%)	0
口の感覚鈍麻	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
鼠径ヘルニア	1 (2.7%)	0
肛門周囲痛	1 (2.7%)	0
直腸分泌物	1 (2.7%)	0
舌潰瘍	1 (2.7%)	0
上部消化管出血	1 (2.7%)	0
嘔吐	1 (2.7%)	1 (2.7%)
血液およびリンパ系障害	14 (37.8%)	6 (16.2%)
好中球減少症	7 (18.9%)	3 (8.1%)
貧血	6 (16.2%)	1 (2.7%)
血小板減少症	4 (10.8%)	2 (5.4%)
白血球減少症	2 (5.4%)	1 (2.7%)
凝血異常	1 (2.7%)	1 (2.7%)
低フィブリノゲン血症	1 (2.7%)	0
リンパ節症	1 (2.7%)	0
代謝および栄養障害	14 (37.8%)	5 (13.5%)
食欲減退	4 (10.8%)	3 (8.1%)
高血糖	3 (8.1%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
低カリウム血症	3 (8.1%)	0
腫瘍崩壊症候群	3 (8.1%)	2 (5.4%)
高尿酸血症	2 (5.4%)	0
低マグネシウム血症	2 (5.4%)	0
糖尿病	1 (2.7%)	0
高トリグリセリド血症	1 (2.7%)	0
低アルブミン血症	1 (2.7%)	0
低カルシウム血症	1 (2.7%)	0
低血糖	1 (2.7%)	0
低ナトリウム血症	1 (2.7%)	1 (2.7%)
低蛋白血症	1 (2.7%)	0
栄養障害	1 (2.7%)	0
ビタミンD欠乏	1 (2.7%)	0
感染症および寄生虫症	13 (35.1%)	2 (5.4%)
帯状疱疹	2 (5.4%)	1 (2.7%)
口腔カンジダ症	2 (5.4%)	0
肺炎	2 (5.4%)	0
気管支炎	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
ＣＯＶＩＤ－１９	1 (2.7%)	0
ＣＯＶＩＤ－１９肺炎	1 (2.7%)	0
蜂巣炎	1 (2.7%)	0
医療機器関連感染	1 (2.7%)	0
蓄膿	1 (2.7%)	0
歯肉炎	1 (2.7%)	0
単純ヘルペス	1 (2.7%)	0
クレブシエラ性菌血症	1 (2.7%)	0
誤嚥性肺炎	1 (2.7%)	0
敗血症	1 (2.7%)	1 (2.7%)
皮膚感染	1 (2.7%)	0
上気道感染	1 (2.7%)	0
ウイルス性上気道感染	1 (2.7%)	0
神経系障害	11 (29.7%)	8 (21.6%)
免疫エフェクター細胞関連神経毒性症候群	4 (10.8%)	4 (10.8%)
浮動性めまい	3 (8.1%)	2 (5.4%)
頭痛	3 (8.1%)	2 (5.4%)
錯感覚	3 (8.1%)	1 (2.7%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
味覚不全	1 (2.7%)	0
書字障害	1 (2.7%)	1 (2.7%)
末梢性感覚ニューロパチー	1 (2.7%)	0
振戦	1 (2.7%)	1 (2.7%)
臨床検査	9 (24.3%)	5 (13.5%)
血小板数減少	5 (13.5%)	3 (8.1%)
好中球数減少	2 (5.4%)	1 (2.7%)
アラニンアミノトランスフェラーゼ増加	1 (2.7%)	1 (2.7%)
アスパラギン酸アミノトランスフェラーゼ増加	1 (2.7%)	1 (2.7%)
血中アルカリホスファターゼ増加	1 (2.7%)	0
γ－グルタミルトランスフェラーゼ増加	1 (2.7%)	0
リンパ球数減少	1 (2.7%)	0
体重減少	1 (2.7%)	0
精神障害	9 (24.3%)	1 (2.7%)
錯乱状態	3 (8.1%)	1 (2.7%)
不眠症	2 (5.4%)	0
快感消失	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
譫妄	1 (2.7%)	0
うつ病	1 (2.7%)	0
感情的苦悩	1 (2.7%)	0
幻覚	1 (2.7%)	0
筋骨格系および結合組織障害	7 (18.9%)	4 (10.8%)
筋肉痛	2 (5.4%)	2 (5.4%)
関節痛	1 (2.7%)	1 (2.7%)
背部痛	1 (2.7%)	0
側腹部痛	1 (2.7%)	0
筋力低下	1 (2.7%)	0
筋骨格痛	1 (2.7%)	0
頚部痛	1 (2.7%)	0
四肢痛	1 (2.7%)	1 (2.7%)
心臓障害	6 (16.2%)	2 (5.4%)
心房細動	1 (2.7%)	0
心血管障害	1 (2.7%)	1 (2.7%)
拡張機能障害	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
心筋炎	1 (2.7%)	1 (2.7%)
洞結節機能不全	1 (2.7%)	0
洞性頻脈	1 (2.7%)	0
傷害、中毒および処置合併症	6 (16.2%)	0
転倒	2 (5.4%)	0
挫傷	1 (2.7%)	0
頭部損傷	1 (2.7%)	0
脊椎圧迫骨折	1 (2.7%)	0
創合併症	1 (2.7%)	0
呼吸器、胸郭および縦隔障害	6 (16.2%)	0
咳嗽	2 (5.4%)	0
呼吸困難	2 (5.4%)	0
胸水	2 (5.4%)	0
乳び胸	1 (2.7%)	0
発声障害	1 (2.7%)	0
鼻閉	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
上気道咳症候群	1 (2.7%)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	5 (13.5%)	2 (5.4%)
基底細胞癌	2 (5.4%)	0
癌疼痛	1 (2.7%)	0
腫瘍フレア	1 (2.7%)	1 (2.7%)
腫瘍疼痛	1 (2.7%)	1 (2.7%)
腎および尿路障害	5 (13.5%)	1 (2.7%)
頻尿	2 (5.4%)	0
急性腎障害	1 (2.7%)	1 (2.7%)
膀胱痙縮	1 (2.7%)	0
排尿困難	1 (2.7%)	0
血尿	1 (2.7%)	0
尿意切迫	1 (2.7%)	0
尿失禁	1 (2.7%)	0
皮膚および皮下組織障害	4 (10.8%)	1 (2.7%)
剥脱性発疹	1 (2.7%)	1 (2.7%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-01 Expansion Part - Subjects in MCL Cohort - Safety Analysis Set

System Organ Class Preferred Term	MCL Cohort (N=37)	
	All	Related
多汗症	1 (2.7%)	0
斑	1 (2.7%)	0
そう痒症	1 (2.7%)	0
発疹	1 (2.7%)	0
皮膚剥脱	1 (2.7%)	0
血管障害	3 (8.1%)	0
低血圧	1 (2.7%)	0
血液量減少性ショック	1 (2.7%)	0
リンパ浮腫	1 (2.7%)	0
表在性静脈血栓症	1 (2.7%)	0
血栓症	1 (2.7%)	0
眼障害	2 (5.4%)	0
眼部腫脹	1 (2.7%)	0
視力障害	1 (2.7%)	0
肝胆道系障害	1 (2.7%)	0
過形成性胆嚢症	1 (2.7%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.

Table 6

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

System Organ Class Preferred Term	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
	All	Related	All	Related	All	Related
Subjects with at least one TEAE	3 (100%)	3 (100%)	6 (100%)	6 (100%)	9 (100%)	9 (100%)
一般・全身障害および投与部位の状態	3 (100%)	3 (100%)	5 (83.3%)	4 (66.7%)	8 (88.9%)	7 (77.8%)
注射部位紅斑	3 (100%)	3 (100%)	2 (33.3%)	2 (33.3%)	5 (55.6%)	5 (55.6%)
注射部位反応	1 (33.3%)	1 (33.3%)	2 (33.3%)	2 (33.3%)	3 (33.3%)	3 (33.3%)
倦怠感	0	0	2 (33.3%)	1 (16.7%)	2 (22.2%)	1 (11.1%)
腋窩痛	0	0	1 (16.7%)	0	1 (11.1%)	0
発熱	0	0	1 (16.7%)	0	1 (11.1%)	0
免疫系障害	3 (100%)	3 (100%)	5 (83.3%)	5 (83.3%)	8 (88.9%)	8 (88.9%)
サイトカイン放出症候群	3 (100%)	3 (100%)	5 (83.3%)	5 (83.3%)	8 (88.9%)	8 (88.9%)
臨床検査	3 (100%)	2 (66.7%)	5 (83.3%)	5 (83.3%)	8 (88.9%)	7 (77.8%)
血小板数減少	2 (66.7%)	1 (33.3%)	2 (33.3%)	1 (16.7%)	4 (44.4%)	2 (22.2%)
好中球数減少	1 (33.3%)	1 (33.3%)	2 (33.3%)	2 (33.3%)	3 (33.3%)	3 (33.3%)
白血球数減少	0	0	3 (50.0%)	3 (50.0%)	3 (33.3%)	3 (33.3%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
System Organ Class Preferred Term	All	Related	All	Related	All	Related
アラニンアミノトランスフェラーゼ増加	1 (33.3%)	1 (33.3%)	1 (16.7%)	0	2 (22.2%)	1 (11.1%)
アスパラギン酸アミノトランスフェラーゼ増加	1 (33.3%)	1 (33.3%)	1 (16.7%)	0	2 (22.2%)	1 (11.1%)
リンパ球数減少	0	0	2 (33.3%)	2 (33.3%)	2 (22.2%)	2 (22.2%)
血中クレアチニン増加	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
心電図ＱＴ延長	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
体重増加	0	0	1 (16.7%)	0	1 (11.1%)	0
皮膚および皮下組織障害	3 (100%)	1 (33.3%)	5 (83.3%)	3 (50.0%)	8 (88.9%)	4 (44.4%)
発疹	1 (33.3%)	1 (33.3%)	1 (16.7%)	1 (16.7%)	2 (22.2%)	2 (22.2%)
斑状丘疹状皮疹	1 (33.3%)	0	1 (16.7%)	1 (16.7%)	2 (22.2%)	1 (11.1%)
接触皮膚炎	0	0	1 (16.7%)	0	1 (11.1%)	0
皮膚乾燥	0	0	1 (16.7%)	0	1 (11.1%)	0
湿疹	1 (33.3%)	0	0	0	1 (11.1%)	0
紅斑	1 (33.3%)	0	0	0	1 (11.1%)	0
そう痒症	1 (33.3%)	0	0	0	1 (11.1%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
System Organ Class Preferred Term	All	Related	All	Related	All	Related
皮膚潰瘍	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
胃腸障害	3 (100%)	2 (66.7%)	4 (66.7%)	2 (33.3%)	7 (77.8%)	4 (44.4%)
悪心	2 (66.7%)	2 (66.7%)	2 (33.3%)	1 (16.7%)	4 (44.4%)	3 (33.3%)
便秘	1 (33.3%)	0	1 (16.7%)	0	2 (22.2%)	0
下痢	1 (33.3%)	1 (33.3%)	1 (16.7%)	1 (16.7%)	2 (22.2%)	2 (22.2%)
口内炎	1 (33.3%)	0	0	0	1 (11.1%)	0
代謝および栄養障害	3 (100%)	3 (100%)	3 (50.0%)	2 (33.3%)	6 (66.7%)	5 (55.6%)
低カリウム血症	0	0	2 (33.3%)	1 (16.7%)	2 (22.2%)	1 (11.1%)
食欲減退	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
高カルシウム血症	1 (33.3%)	0	0	0	1 (11.1%)	0
高カリウム血症	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
高尿酸血症	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
低アルブミン血症	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
低フェリチン血症	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
System Organ Class Preferred Term	All	Related	All	Related	All	Related
低ナトリウム血症	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
低リン血症	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
腫瘍崩壊症候群	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
血液およびリンパ系障害	2 (66.7%)	1 (33.3%)	3 (50.0%)	3 (50.0%)	5 (55.6%)	4 (44.4%)
貧血	1 (33.3%)	1 (33.3%)	3 (50.0%)	3 (50.0%)	4 (44.4%)	4 (44.4%)
好酸球増加症	1 (33.3%)	0	0	0	1 (11.1%)	0
神経系障害	1 (33.3%)	1 (33.3%)	2 (33.3%)	1 (16.7%)	3 (33.3%)	2 (22.2%)
意識レベルの低下	0	0	1 (16.7%)	0	1 (11.1%)	0
味覚不全	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
頭痛	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
下肢静止不能症候群	1 (33.3%)	0	0	0	1 (11.1%)	0
精神障害	1 (33.3%)	0	2 (33.3%)	1 (16.7%)	3 (33.3%)	1 (11.1%)
不眠症	1 (33.3%)	0	1 (16.7%)	0	2 (22.2%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
System Organ Class Preferred Term	All	Related	All	Related	All	Related
激越	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
心臓障害	2 (66.7%)	2 (66.7%)	0	0	2 (22.2%)	2 (22.2%)
心房細動	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
心室性不整脈	1 (33.3%)	1 (33.3%)	0	0	1 (11.1%)	1 (11.1%)
呼吸器、胸郭および縦隔障害	0	0	2 (33.3%)	1 (16.7%)	2 (22.2%)	1 (11.1%)
鼻閉	0	0	1 (16.7%)	0	1 (11.1%)	0
口腔咽頭痛	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
内分泌障害	0	0	1 (16.7%)	0	1 (11.1%)	0
副腎肥大	0	0	1 (16.7%)	0	1 (11.1%)	0
感染症および寄生虫症	0	0	1 (16.7%)	0	1 (11.1%)	0
外耳炎	0	0	1 (16.7%)	0	1 (11.1%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Escalation Part - Subjects in All Cohorts - Safety Analysis Set

	All Cohorts					
	24 mg (N=3)		48 mg (N=6)		Overall (N=9)	
System Organ Class Preferred Term	All	Related	All	Related	All	Related
筋骨格系および結合組織障害	0	0	1 (16.7%)	0	1 (11.1%)	0
頚部痛	0	0	1 (16.7%)	0	1 (11.1%)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	0	0	1 (16.7%)	0	1 (11.1%)	0
癌疼痛	0	0	1 (16.7%)	0	1 (11.1%)	0
腎および尿路障害	0	0	1 (16.7%)	0	1 (11.1%)	0
慢性腎臓病	0	0	1 (16.7%)	0	1 (11.1%)	0
血管障害	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)
高血圧	0	0	1 (16.7%)	1 (16.7%)	1 (11.1%)	1 (11.1%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Table 7

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36) All	 Related
Subjects with at least one TEAE	36 (100%)	36 (100%)
一般・全身障害および投与部位の状態	30 (83.3%)	27 (75.0%)
注射部位反応	21 (58.3%)	21 (58.3%)
倦怠感	7 (19.4%)	5 (13.9%)
注射部位紅斑	4 (11.1%)	4 (11.1%)
浮腫	3 (8.3%)	2 (5.6%)
発熱	3 (8.3%)	3 (8.3%)
全身性浮腫	1 (2.8%)	0
疼痛	1 (2.8%)	0
免疫系障害	30 (83.3%)	30 (83.3%)
サイトカイン放出症候群	30 (83.3%)	30 (83.3%)
臨床検査	25 (69.4%)	21 (58.3%)
好中球数減少	13 (36.1%)	11 (30.6%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Tigermed¥GEN3013-04¥t_14_3_1_2_1_a.sas¥T_14_3_1_2_1_b
Database lock date: [redacted]20[redacted]; Data Cutoff: 31Jan2022; Date Generated: [redacted]20[redacted] 23:00

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36) All	 Related
リンパ球数減少	9 (25.0%)	7 (19.4%)
血小板数減少	8 (22.2%)	7 (19.4%)
白血球数減少	7 (19.4%)	5 (13.9%)
アラニンアミノトランスフェラーゼ増加	5 (13.9%)	2 (5.6%)
アスパラギン酸アミノトランスフェラーゼ増加	4 (11.1%)	2 (5.6%)
血中クレアチニン増加	3 (8.3%)	1 (2.8%)
体重減少	2 (5.6%)	0
血中ビリルビン増加	1 (2.8%)	1 (2.8%)
血中乳酸脱水素酵素増加	1 (2.8%)	0
γ－グルタミルトランスフェラーゼ増加	1 (2.8%)	0
免疫グロブリン減少	1 (2.8%)	1 (2.8%)
リンパ球数増加	1 (2.8%)	1 (2.8%)
総蛋白減少	1 (2.8%)	1 (2.8%)
体重増加	1 (2.8%)	0
白血球数増加	1 (2.8%)	1 (2.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
胃腸障害	22 (61.1%)	12 (33.3%)
悪心	7 (19.4%)	2 (5.6%)
便秘	6 (16.7%)	2 (5.6%)
下痢	4 (11.1%)	3 (8.3%)
嘔吐	4 (11.1%)	3 (8.3%)
口内炎	3 (8.3%)	2 (5.6%)
腹痛	2 (5.6%)	0
痔核	2 (5.6%)	0
胃酸過多	1 (2.8%)	1 (2.8%)
肛門周囲痛	1 (2.8%)	0
代謝および栄養障害	20 (55.6%)	14 (38.9%)
低カリウム血症	10 (27.8%)	5 (13.9%)
食欲減退	8 (22.2%)	7 (19.4%)
低アルブミン血症	4 (11.1%)	4 (11.1%)
低血糖	2 (5.6%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
低ナトリウム血症	2 (5.6%)	0
糖尿病	1 (2.8%)	0
高カルシウム血症	1 (2.8%)	0
高カリウム血症	1 (2.8%)	0
高尿酸血症	1 (2.8%)	1 (2.8%)
低リン血症	1 (2.8%)	1 (2.8%)
皮膚および皮下組織障害	17 (47.2%)	11 (30.6%)
発疹	7 (19.4%)	7 (19.4%)
皮膚乾燥	2 (5.6%)	1 (2.8%)
湿疹	2 (5.6%)	0
多形紅斑	2 (5.6%)	2 (5.6%)
ざ瘡	1 (2.8%)	0
脱毛症	1 (2.8%)	1 (2.8%)
薬疹	1 (2.8%)	0
紅斑	1 (2.8%)	1 (2.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
爪の障害	1 (2.8%)	0
斑状丘疹状皮疹	1 (2.8%)	0
皮膚剥脱	1 (2.8%)	0
感染症および寄生虫症	16 (44.4%)	10 (27.8%)
尿路感染	4 (11.1%)	2 (5.6%)
気管支炎	2 (5.6%)	2 (5.6%)
単純ヘルペス	2 (5.6%)	2 (5.6%)
肺炎	2 (5.6%)	2 (5.6%)
肛門直腸感染	1 (2.8%)	1 (2.8%)
結膜炎	1 (2.8%)	0
サイトメガロウイルス性腸炎	1 (2.8%)	0
サイトメガロウイルス感染	1 (2.8%)	1 (2.8%)
サイトメガロウイルス血症	1 (2.8%)	1 (2.8%)
帯状疱疹	1 (2.8%)	1 (2.8%)
上咽頭炎	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
歯周炎	1 (2.8%)	0
敗血症	1 (2.8%)	0
歯膿瘍	1 (2.8%)	0
血液およびリンパ系障害	9 (25.0%)	7 (19.4%)
貧血	4 (11.1%)	2 (5.6%)
発熱性好中球減少症	1 (2.8%)	1 (2.8%)
白血球減少症	1 (2.8%)	1 (2.8%)
リンパ節痛	1 (2.8%)	1 (2.8%)
リンパ球減少症	1 (2.8%)	1 (2.8%)
好中球減少症	1 (2.8%)	1 (2.8%)
血小板減少症	1 (2.8%)	1 (2.8%)
神経系障害	8 (22.2%)	2 (5.6%)
頭痛	3 (8.3%)	0
感覚鈍麻	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36) All	 Related
免疫エフェクター細胞関連神経毒性症候群	1 (2.8%)	1 (2.8%)
嗅覚錯誤	1 (2.8%)	1 (2.8%)
ヘルペス後神経痛	1 (2.8%)	0
傾眠	1 (2.8%)	0
筋骨格系および結合組織障害	7 (19.4%)	1 (2.8%)
背部痛	3 (8.3%)	0
関節痛	2 (5.6%)	0
筋力低下	2 (5.6%)	1 (2.8%)
関節炎	1 (2.8%)	0
筋肉痛	1 (2.8%)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	7 (19.4%)	1 (2.8%)
腫瘍疼痛	3 (8.3%)	0
癌疼痛	1 (2.8%)	0
慢性骨髄単球性白血病	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36) All	 Related
膵癌	1 (2.8%)	0
扁平上皮癌	1 (2.8%)	0
腫瘍フレア	1 (2.8%)	1 (2.8%)
呼吸器、胸郭および縦隔障害	7 (19.4%)	2 (5.6%)
咳嗽	2 (5.6%)	0
発声障害	2 (5.6%)	1 (2.8%)
低酸素症	2 (5.6%)	0
胸水	1 (2.8%)	0
気胸	1 (2.8%)	0
アレルギー性鼻炎	1 (2.8%)	1 (2.8%)
精神障害	6 (16.7%)	0
不眠症	3 (8.3%)	0
激越	1 (2.8%)	0
不安	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
譫妄	1 (2.8%)	0
幻覚	1 (2.8%)	0
腎および尿路障害	5 (13.9%)	1 (2.8%)
排尿困難	2 (5.6%)	1 (2.8%)
水腎症	1 (2.8%)	0
緊張性膀胱	1 (2.8%)	0
腎障害	1 (2.8%)	0
尿管結石症	1 (2.8%)	0
尿閉	1 (2.8%)	1 (2.8%)
眼障害	3 (8.3%)	0
結膜出血	1 (2.8%)	0
緑内障	1 (2.8%)	0
眼充血	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36) All	 Related
眼瞼腫脹	1 (2.8%)	0
傷害、中毒および処置合併症	3 (8.3%)	0
転倒	2 (5.6%)	0
爪損傷	1 (2.8%)	0
硬膜下血腫	1 (2.8%)	0
耳および迷路障害	2 (5.6%)	1 (2.8%)
回転性めまい	2 (5.6%)	1 (2.8%)
心臓障害	1 (2.8%)	0
洞性頻脈	1 (2.8%)	0
生殖系および乳房障害	1 (2.8%)	0
良性前立腺肥大症	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in aNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	DLBCL (N=36)	
	All	Related
血管障害	1 (2.8%)	0
塞栓症	1 (2.8%)	0
低血圧	1 (2.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Table 8

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
Subjects with at least one TEAE	21 (100%)	21 (100%)
免疫系障害	19 (90.5%)	19 (90.5%)
サイトカイン放出症候群	19 (90.5%)	19 (90.5%)
低γグロブリン血症	2 (9.5%)	2 (9.5%)
免疫系障害	1 (4.8%)	0
皮膚および皮下組織障害	16 (76.2%)	12 (57.1%)
発疹	8 (38.1%)	6 (28.6%)
紅斑	3 (14.3%)	3 (14.3%)
皮膚乾燥	1 (4.8%)	1 (4.8%)
湿疹	1 (4.8%)	0
そう痒症	1 (4.8%)	0
斑状丘疹状皮疹	1 (4.8%)	1 (4.8%)
脂漏性皮膚炎	1 (4.8%)	0
皮膚剥脱	1 (4.8%)	1 (4.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
皮膚硬結	1 (4.8%)	0
毛細血管拡張症	1 (4.8%)	1 (4.8%)
蕁麻疹	1 (4.8%)	1 (4.8%)
一般・全身障害および投与部位の状態	15 (71.4%)	15 (71.4%)
注射部位反応	14 (66.7%)	14 (66.7%)
発熱	4 (19.0%)	1 (4.8%)
倦怠感	3 (14.3%)	2 (9.5%)
顔面浮腫	2 (9.5%)	1 (4.8%)
低体温	1 (4.8%)	0
注射部位紅斑	1 (4.8%)	1 (4.8%)
末梢性浮腫	1 (4.8%)	1 (4.8%)
離脱症候群	1 (4.8%)	0
胃腸障害	11 (52.4%)	3 (14.3%)
便秘	4 (19.0%)	1 (4.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
下痢	2 (9.5%)	1 (4.8%)
悪心	2 (9.5%)	1 (4.8%)
腹部不快感	1 (4.8%)	0
齲歯	1 (4.8%)	0
胃炎	1 (4.8%)	0
口内炎	1 (4.8%)	0
嘔吐	1 (4.8%)	0
臨床検査	11 (52.4%)	9 (42.9%)
アラニンアミノトランスフェラーゼ増加	6 (28.6%)	5 (23.8%)
アスパラギン酸アミノトランスフェラーゼ増加	6 (28.6%)	5 (23.8%)
好中球数減少	5 (23.8%)	4 (19.0%)
リンパ球数減少	3 (14.3%)	3 (14.3%)
γ－グルタミルトランスフェラーゼ増加	2 (9.5%)	2 (9.5%)
血中ブドウ糖増加	1 (4.8%)	0
フィブリンDダイマー増加	1 (4.8%)	1 (4.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
免疫グロブリン減少	1 (4.8%)	1 (4.8%)
白血球数減少	1 (4.8%)	1 (4.8%)
代謝および栄養障害	9 (42.9%)	4 (19.0%)
高血糖	3 (14.3%)	0
食欲減退	2 (9.5%)	1 (4.8%)
低カリウム血症	2 (9.5%)	0
高脂血症	1 (4.8%)	0
高尿酸血症	1 (4.8%)	0
低アルブミン血症	1 (4.8%)	1 (4.8%)
低カルシウム血症	1 (4.8%)	1 (4.8%)
低血糖	1 (4.8%)	0
低リン血症	1 (4.8%)	1 (4.8%)
感染症および寄生虫症	6 (28.6%)	3 (14.3%)
結膜炎	2 (9.5%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
気管支炎	1 (4.8%)	0
膀胱炎	1 (4.8%)	0
サイトメガロウイルス感染	1 (4.8%)	0
毛包炎	1 (4.8%)	1 (4.8%)
帯状疱疹	1 (4.8%)	1 (4.8%)
口腔ヘルペス	1 (4.8%)	1 (4.8%)
細菌性肺炎	1 (4.8%)	0
肺炎球菌性肺炎	1 (4.8%)	0
副鼻腔炎	1 (4.8%)	0
精神障害	6 (28.6%)	1 (4.8%)
不眠症	5 (23.8%)	0
幻覚	1 (4.8%)	1 (4.8%)
筋骨格系および結合組織障害	5 (23.8%)	1 (4.8%)
背部痛	2 (9.5%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21) All	 Related
関節痛	1 (4.8%)	1 (4.8%)
筋骨格系胸痛	1 (4.8%)	0
筋肉痛	1 (4.8%)	0
神経系障害	4 (19.0%)	2 (9.5%)
脳血管発作	1 (4.8%)	0
浮動性めまい	1 (4.8%)	1 (4.8%)
頭痛	1 (4.8%)	0
感覚鈍麻	1 (4.8%)	1 (4.8%)
末梢性ニューロパチー	1 (4.8%)	1 (4.8%)
ヘルペス後神経痛	1 (4.8%)	0
傾眠	1 (4.8%)	0
失神	1 (4.8%)	0
呼吸器、胸郭および縦隔障害	4 (19.0%)	0
咳嗽	3 (14.3%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21)	
	All	Related
しゃっくり	1 (4.8%)	0
傷害、中毒および処置合併症	3 (14.3%)	0
節足動物咬傷	1 (4.8%)	0
転倒	1 (4.8%)	0
ワクチン接種合併症	1 (4.8%)	0
眼障害	2 (9.5%)	0
結膜出血	1 (4.8%)	0
緑内障	1 (4.8%)	0
血管障害	2 (9.5%)	1 (4.8%)
高血圧	1 (4.8%)	0
低血圧	1 (4.8%)	1 (4.8%)

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.

Summary of Treatment-Emergent Adverse Events by SOC and PT
GCT3013-04 Expansion Part - Subjects in iNHL Cohort - Safety Analysis Set

System Organ Class Preferred Term	FL (N=21)	
	All	Related
血液およびリンパ系障害	1 (4.8%)	0
発熱性好中球減少症	1 (4.8%)	0
内分泌障害	1 (4.8%)	0
クッシング様症状	1 (4.8%)	0
良性、悪性および詳細不明の新生物（嚢胞およびポリープを含む）	1 (4.8%)	0
胃癌	1 (4.8%)	0
腎および尿路障害	1 (4.8%)	0
排尿困難	1 (4.8%)	0

Note: Percentages calculated based on number of subjects in Safety Analysis Set.
Note: Adverse events are classified using MedDRA v24.1 and are counted only once per system organ class and only once per preferred term.
Note: Sort by decreasing frequency of SOC and decreasing frequency of PT in the overall (All) column, sorting alphabetically for ties.